var title_f31_52_32576="Scleral tuberculosis";
var content_f31_52_32576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scleral tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multinodular scleral mass in the left eye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:Saini, JS, Sharma, A, Pillai, P. Trop Geogr Med 1988; 40:350.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32576=[""].join("\n");
var outline_f31_52_32576=null;
var title_f31_52_32577="CF vit preps fat sol";
var content_f31_52_32577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58288%7EPEDS%2F67006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58288%7EPEDS%2F67006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fat-soluble vitamins preparations for individuals with cystic fibrosis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        SourceCF&reg; (drops, chewables, softgels)",
"       </td>",
"       <td class=\"subtitle1\">",
"        AquADEK&reg; (chewables)",
"       </td>",
"       <td class=\"subtitle1\">",
"        AquADEKs&reg; (drops, softgels)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamax&reg; (drops, chewables)",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Poly-Vi-Sol&reg; (drops)",
"        </p>",
"        <p>",
"         Centrum&reg; (chewable, tablet)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Total Vitamin A (International Units, IU) (Retinol and Beta Carotene)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-12 months",
"       </td>",
"       <td>",
"        <p>",
"         4627 IU/1 mL",
"        </p>",
"        <p>",
"         75 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        <p>",
"         5751 IU/1 mL",
"        </p>",
"        <p>",
"         87 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        3170 IU/1 mL as 100 percent retinol palmitate",
"       </td>",
"       <td>",
"        1500 IU/1 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 yrs",
"       </td>",
"       <td>",
"        <p>",
"         9254 IU/2 mL",
"        </p>",
"        <p>",
"         75 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        <p>",
"         11,502 IU/2 mL",
"        </p>",
"        <p>",
"         87 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        6340 IU/2 mL as 100 percent retinol palmitate",
"       </td>",
"       <td>",
"        3000 IU/2 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-8 yrs",
"       </td>",
"       <td>",
"        <p>",
"         16,000 IU/1 chewable",
"        </p>",
"        <p>",
"         88 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         18,167 IU/2 chewables",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         18,167 IU/1 softgel",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         5000 IU/1 chewable",
"        </p>",
"        <p>",
"         50 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         3500 IU/1 chewable",
"        </p>",
"        <p>",
"         29 percent as beta-carotene",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-18 yrs",
"       </td>",
"       <td>",
"        <p>",
"         32,000 IU/2 softgels",
"        </p>",
"        <p>",
"         88 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         36,334 IU/4 chewables",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         36,334 IU/2 softgels",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         10,000 IU/2 chewables",
"        </p>",
"        <p>",
"         50 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         7000 IU/2 tablets",
"        </p>",
"        <p>",
"         29 percent as beta-carotene",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;18 yrs",
"       </td>",
"       <td>",
"        <p>",
"         32,000 IU/2 softgels",
"        </p>",
"        <p>",
"         88 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         36,334 IU/4 chewables",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         36,334 IU/2 softgels",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         10,000 IU/2 chewables",
"        </p>",
"        <p>",
"         50 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         7000 IU/2 tablets",
"        </p>",
"        <p>",
"         29 percent as beta-carotene",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Vitamin E (International Units, IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-12 months",
"       </td>",
"       <td>",
"        50 IU/1 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        50 IU/1 mL",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        50 IU/1 mL",
"       </td>",
"       <td>",
"        5 IU/1 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 yrs",
"       </td>",
"       <td>",
"        100 IU/2 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        100 IU/2 mL",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        100 IU/2 mL",
"       </td>",
"       <td>",
"        10 IU/2 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-8 yrs",
"       </td>",
"       <td>",
"        200 IU/1 chewable",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         100 IU/2 chewables",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         150 IU/1 softgel",
"        </p>",
"       </td>",
"       <td>",
"        200 IU/1 chewable",
"       </td>",
"       <td>",
"        30 IU/1 chewable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-18 yrs",
"       </td>",
"       <td>",
"        400 IU/2 softgels",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        200 IU/4 chewables",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         300 IU/2 softgels",
"        </p>",
"       </td>",
"       <td>",
"        400 IU/2 chewables",
"       </td>",
"       <td>",
"        60 IU/2 tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;18 yrs",
"       </td>",
"       <td>",
"        400 IU/2 softgels",
"       </td>",
"       <td>",
"        200 IU/4 chewables",
"       </td>",
"       <td>",
"        300 IU/2 softgels",
"       </td>",
"       <td>",
"        400 IU/2 chewables",
"       </td>",
"       <td>",
"        60 IU/2 tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Vitamin D (International Units, IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-12 months",
"       </td>",
"       <td>",
"        500 IU/1 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        400 IU/1 mL",
"       </td>",
"       <td>",
"        400 IU/1 mL",
"       </td>",
"       <td>",
"        400 IU/1 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 yrs",
"       </td>",
"       <td>",
"        1000 IU/2 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        800 IU/2 mL",
"       </td>",
"       <td>",
"        800 IU/2 mL",
"       </td>",
"       <td>",
"        800 IU/2 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-8 yrs",
"       </td>",
"       <td>",
"        1000 IU/1 chewable",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         800 IU/2 chewables",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         800 IU/1 softgel",
"        </p>",
"       </td>",
"       <td>",
"        400 IU/1 chewable",
"       </td>",
"       <td>",
"        400 IU/1 chewable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-18 yrs",
"       </td>",
"       <td>",
"        2000 IU/2 softgels",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         1600 IU/4 chewables",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         1600 IU/2 softgels",
"        </p>",
"       </td>",
"       <td>",
"        800 IU/2 chewables",
"       </td>",
"       <td>",
"        800 IU/2 tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;18 yrs",
"       </td>",
"       <td>",
"        2000 IU/2 softgels",
"       </td>",
"       <td>",
"        1600 IU/4 chewables",
"       </td>",
"       <td>",
"        1600 IU/2 softgels",
"       </td>",
"       <td>",
"        800 IU/2 chewables",
"       </td>",
"       <td>",
"        800 IU/2 tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Vitamin K (mcg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-12 months",
"       </td>",
"       <td>",
"        400 mcg/1 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        400 mcg/1 mL",
"       </td>",
"       <td>",
"        300 mcg/1 mL",
"       </td>",
"       <td>",
"        0 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 yrs",
"       </td>",
"       <td>",
"        800 mcg/2 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        800 mcg/2 mL",
"       </td>",
"       <td>",
"        600 mcg/2 mL",
"       </td>",
"       <td>",
"        0 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-8 yrs",
"       </td>",
"       <td>",
"        800 mcg/1 chewable",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         700 mcg/2 chewables",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         700 mcg/1 softgel",
"        </p>",
"       </td>",
"       <td>",
"        200 mcg/1 chewable",
"       </td>",
"       <td>",
"        10 mcg/1 chewable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-18 yrs",
"       </td>",
"       <td>",
"        1600 mcg/2 softgels",
"       </td>",
"       <td>",
"        1400 mcg/4 chewables",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         1400 mcg/2 softgels",
"        </p>",
"       </td>",
"       <td>",
"        400 mcg/2 chewables",
"       </td>",
"       <td>",
"        50 mcg/2 tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;18 yrs",
"       </td>",
"       <td>",
"        1600 mcg/2 softgels",
"       </td>",
"       <td>",
"        1400 mcg/4 chewables",
"       </td>",
"       <td>",
"        1400 mcg/2 softgels",
"       </td>",
"       <td>",
"        400 mcg/2 chewables",
"       </td>",
"       <td>",
"        50 mcg/2 tablets",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    AquADEKs&reg; is a registered trademark of Yasoo Health Inc, Vitamax&reg; is a registered trademark of Shear/Kershman Labs. Inc, Poly-Vi-Sol&reg; is a registered trademark of Mead Johnson and Company, Centrum&reg; is a registered trademark of Wyeth Consumer Care.",
"    <div class=\"footnotes\">",
"     * The content of this table was confirmed with each company as of December 2008.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Also contains mixed tocopherols.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eurand Pharmaceuticals, Inc. All rights reserved. Available at: file://www.sourcecf.com/pdf/VitaminComparisonTablenew.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Supplements of water-soluble vitamins and zinc for individuals with cystic fibrosis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Age",
"      </td>",
"      <td class=\"subtitle1\">",
"       SourceCF&reg; (drops, chewables, softgels)",
"      </td>",
"      <td class=\"subtitle1\">",
"       ADEKs&reg; (chewables)",
"      </td>",
"      <td class=\"subtitle1\">",
"       AQUADEKs&reg; (drops, softgels)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Vitamax&reg; (drops, chewables)",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        Poly-Vi-Sol&reg; (drops)",
"       </p>",
"       <p>",
"        Centrum&reg; (chewable, tablet)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Thiamin B1 (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       0.5 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       0.5 mg/1 mL",
"      </td>",
"      <td>",
"       0.5 mg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       1 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       1 mg/2 mL",
"      </td>",
"      <td>",
"       1 mg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       1.5 mg/1 chewable",
"      </td>",
"      <td>",
"       1.2 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        1.5 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       1.5 mg/1 chewable",
"      </td>",
"      <td>",
"       1.5 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       3 mg/2 softgels",
"      </td>",
"      <td>",
"       2.4 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        3 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       3 mg/2 chewables",
"      </td>",
"      <td>",
"       3 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Riboflavin B2 (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       1.7 mg/1 chewable",
"      </td>",
"      <td>",
"       1.3 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        1.7 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       1.7 mg/1 chewable",
"      </td>",
"      <td>",
"       1.7 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       3.4 mg/2 softgels",
"      </td>",
"      <td>",
"       2.6 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        3.4 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       3.4 mg/2 chewables",
"      </td>",
"      <td>",
"       3.4 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Niacin (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       6 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       6 mg/1 mL",
"      </td>",
"      <td>",
"       6 mg/1 mL",
"      </td>",
"      <td>",
"       8 mg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       12 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       12 mg/2 mL",
"      </td>",
"      <td>",
"       12 mg/2 mL",
"      </td>",
"      <td>",
"       16 mg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       10 mg/1 chewable",
"      </td>",
"      <td>",
"       10 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        20 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       20 mg/1 chewable",
"      </td>",
"      <td>",
"       20 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       40 mg/2 softgels",
"      </td>",
"      <td>",
"       20 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        40 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       40 mg/ 2 chewables",
"      </td>",
"      <td>",
"       40 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Pyridoxine B6 (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       0.4 mg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       0.8 mg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       1.9 mg/1 chewable",
"      </td>",
"      <td>",
"       1.5 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        1.9 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       2 mg/1 chewable",
"      </td>",
"      <td>",
"       2 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       3.8 mg/2 softgels",
"      </td>",
"      <td>",
"       3 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        3.8 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       4 mg/2 chewables",
"      </td>",
"      <td>",
"       4 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       B12 (mcg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       4 mcg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       4 mcg/1 mL",
"      </td>",
"      <td>",
"       2 mcg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       8 mcg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       8 mcg/2 mL",
"      </td>",
"      <td>",
"       4 mcg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       6 mcg/1 chewable",
"      </td>",
"      <td>",
"       12 mcg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        12 mcg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       6 mcg/1 chewable",
"      </td>",
"      <td>",
"       6 mcg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       12 mcg/2 softgels",
"      </td>",
"      <td>",
"       24 mcg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        24 mcg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       12 mcg/2 chewables",
"      </td>",
"      <td>",
"       12 mcg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Biotin (mcg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       15 mcg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       15 mcg/1 mL",
"      </td>",
"      <td>",
"       15 mcg/1 mL",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       30 mcg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       30 mcg/2 mL",
"      </td>",
"      <td>",
"       30 mcg/2 mL",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       100 mcg/1 chewable",
"      </td>",
"      <td>",
"       50 mcg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        100 mcg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       300 mcg/1 chewable",
"      </td>",
"      <td>",
"       45 mcg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       200 mcg/2 softgels",
"      </td>",
"      <td>",
"       100 mcg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        200 mcg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       600 mcg/2 chewables",
"      </td>",
"      <td>",
"       60 mcg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Folic Acid (mcg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       200 mcg/1 chewable",
"      </td>",
"      <td>",
"       200 mcg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        200 mcg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       200 mcg/1 chewable",
"      </td>",
"      <td>",
"       400 mcg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       400 mcg/2 softgels",
"      </td>",
"      <td>",
"       400 mcg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        400 mcg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       400 mcg/2 chewables",
"      </td>",
"      <td>",
"       800 mcg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Ascorbic Acid C (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       45 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       45 mg/1 mL",
"      </td>",
"      <td>",
"       45 mg/1 mL",
"      </td>",
"      <td>",
"       35 mg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       90 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       90 mg/2 mL",
"      </td>",
"      <td>",
"       90 mg/2 mL",
"      </td>",
"      <td>",
"       70 mg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       100 mg/1 chewable",
"      </td>",
"      <td>",
"       60 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        75 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       60 mg/1 chewable",
"      </td>",
"      <td>",
"       60 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       200 mg/2 softgels",
"      </td>",
"      <td>",
"       120 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        150 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       120 mg/2 chewables",
"      </td>",
"      <td>",
"       120 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Pantothenic Acid (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       3 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       3 mg/1 mL",
"      </td>",
"      <td>",
"       3 mg/1 mL",
"      </td>",
"      <td>",
"       0 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       6 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       6 mg/2 mL",
"      </td>",
"      <td>",
"       6 mg/2 mL",
"      </td>",
"      <td>",
"       0 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       12 mg/1 chewable",
"      </td>",
"      <td>",
"       10 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        12 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       10 mg/1 chewable",
"      </td>",
"      <td>",
"       10 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       24 mg/2 softgels",
"      </td>",
"      <td>",
"       20 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        24 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       20 mg/2 chewables",
"      </td>",
"      <td>",
"       20 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Zinc (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       5 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       5 mg/1 mL",
"      </td>",
"      <td>",
"       7.5 mg/1 mL",
"      </td>",
"      <td>",
"       0 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       10 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       10 mg/2 mL",
"      </td>",
"      <td>",
"       15 mg/2 mL",
"      </td>",
"      <td>",
"       0 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       15 mg/1 chewable",
"      </td>",
"      <td>",
"       7.5 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        10 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       7.5 mg/1 chewable",
"      </td>",
"      <td>",
"       15 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       30 mg/2 softgels",
"      </td>",
"      <td>",
"       15 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        20 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       15 mg/2 chewables",
"      </td>",
"      <td>",
"       22 mg/2 tablets",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The content of this table was confirmed with each company as of December 2008.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eurand Pharmaceuticals, Inc. All rights reserved. Available at: file://www.sourcecf.com/pdf/VitaminComparisonTablenew.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32577=[""].join("\n");
var outline_f31_52_32577=null;
var title_f31_52_32578="M mode phono mitral stenosis";
var content_f31_52_32578=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram of mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal mitral valve, the anterior (aML), and posterior leaflets (pML) are seen in panel A; the e-f slope is normal. The valve thickness, as demonstrated between the arrows, is not increased. Panel B is the M-mode echocardiogram of a severely stenotic mitral valve; the e-f slope is reduced, atrial contraction (a wave) is dimunitive, and the valve thickness is increase (between arrows). The simultaneous phonocardiogram demonstrates a short interval (0.9 sec) between the second sound and opening snap (OS) and a presystolic low-frequency murmur resulting from atrial contraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32578=[""].join("\n");
var outline_f31_52_32578=null;
var title_f31_52_32579="Halcinonide: Patient drug information";
var content_f31_52_32579=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Halcinonide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/45/15060?source=see_link\">",
"     see \"Halcinonide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Halog&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to halcinonide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697930",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Burning.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12527 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32579=[""].join("\n");
var outline_f31_52_32579=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178345\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014854\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014853\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014858\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014859\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014861\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014856\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014857\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014862\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014863\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/45/15060?source=related_link\">",
"      Halcinonide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_52_32580="Left lung atelectasis";
var content_f31_52_32580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete atelectasis of the left lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bedside chest radiograph of a intubated patient with complete left lung atelectasis. The endotracheal tube was advanced too far into the airway, obstructing the left mainstem bronchus. The left hemithorax is completely opaque. The cardiac silhouette is totally obscured due to its deviation into the left hemithorax.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32580=[""].join("\n");
var outline_f31_52_32580=null;
var title_f31_52_32581="Hemoperfusion";
var content_f31_52_32581=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemoperfusion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32581/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32581/contributors\">",
"     James F Winchester, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32581/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32581/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32581/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32581/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/52/32581/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoperfusion consists of the passage of anticoagulated blood through a device, usually a column, that contains adsorbent particles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/1\">",
"     1",
"    </a>",
"    ]. Introduced in the 1940s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/2\">",
"     2",
"    </a>",
"    ], the technique was refined during 1950 to 1970, and then introduced clinically for the treatment of poisoning in the 1970s and 1980s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Despite its availability, this technique is only infrequently utilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of adsorbent particle utilized within a hemoperfusion device may vary. The most commonly available particles are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    and resin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Charcoal hemoperfusion has been used to treat a variety of conditions, including poisoning and hepatic failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Certain resins (polystyrene &mdash; XAD series) are most effective for the removal of lipid-soluble drugs, with drug clearance rates from the blood frequently exceeding those achieved by charcoal hemoperfusion. Although available in Europe, they are no longer available in the United States since the market was limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antibody or antigen-coated charcoal hemoperfusion is also available for specific autoimmune states; they have been used infrequently for systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/7\">",
"     7",
"    </a>",
"    ] and rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], and to remove pathogenic anti-HLA antibodies in some renal transplant candidates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, removal of endotoxin in septic shock has been achieved with a hemoperfusion device consisting of inert fibers coated with the antibiotic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    , which adsorbs endotoxin, with some clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34570?source=see_link&amp;anchor=H11#H11\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\", section on 'HLA sensitization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early hemoperfusion devices produced significant side effects, such as facial flushing, dyspnea, burning sensations, thrombocytopenia, and reduced fibrinogen concentrations. These adverse effects have been largely overcome with modern preparatory methods, including selecting less fragile starting materials, washing, and, most importantly, coating of absorbents with a polymer solution that reduces platelet aggregation.",
"   </p>",
"   <p>",
"    An overview of hemoperfusion, including the clinical settings in which this technology may be considered, is reviewed here. A general introduction to the treatment of poisoning as well as a discussion of the use of other technologies in this setting, such as hemodialysis and peritoneal dialysis, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of hemoperfusion in the treatment of specific intoxications, such as valproic acid,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/43/19125?source=see_link\">",
"     meprobamate",
"    </a>",
"    , are also discussed elsewhere. (See appropriate topic reviews)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSICAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoperfusion depends upon the physical adsorption of chemicals. With",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    , drugs are irreversibly bound via van der Waals' forces; with resins, drugs are not irreversibly bound and can be eluted with organic solvents; in the case of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    , endotoxin is bound by chemi-sorption.",
"   </p>",
"   <p>",
"    Water and lipid soluble substances with molecular weights ranging from 100 to 40,000 daltons are well adsorbed with hemoperfusion. Charcoal has greater affinity for water soluble molecules, while resins have greater affinity for lipid soluble molecules. Chemicals at higher molecular weights are adsorbed less efficiently to polymer coated charcoal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many cases, drug removal (in terms of clearance) is superior with hemoperfusion than with hemodialysis, peritoneal dialysis, or forced diuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/13\">",
"     13",
"    </a>",
"    ]. In general, hemoperfusion is preferred to hemodialysis for the removal of chemicals that are lipid soluble or are highly protein bound. Hemodialysis is preferred for water-soluble low molecular weight compounds, since these compounds readily cross hemodialysis membranes. However, with the advent of high flux dialysis membranes for routine hemodialysis, the advantage of hemoperfusion over cuprophane dialyzers has lessened, since high flux membrane drug removal may be equal to that of hemoperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEMOPERFUSION METHODOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoperfusion is conducted using dialysis blood lines, a blood pump, pressure gauges, and a column that contains between 100 and 300 gm of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    or 650 gm of polystyrene resin. A list of some of the clinically available hemoperfusion devices and the contained sorbents is shown in this table (",
"    <a class=\"graphic graphic_table graphicRef79263 \" href=\"mobipreview.htm?2/61/3035\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The choice of cartridge depends upon body size, and drug involved. As examples, a small cartridge is utilized for a child, while XAD-4 should be used for a lipid soluble drug, such as glutethimide.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    requirements are similar to hemodialysis, and it is recommended to keep the activated clotting time (ACT) approximately 2 to 2.5 times normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38120?source=see_link\">",
"     \"Hemodialysis anticoagulation\"",
"    </a>",
"    .) Priming and flushing of the devices is achieved with normal saline.",
"   </p>",
"   <p>",
"    To perform hemoperfusion, anticoagulated blood is withdrawn through a temporary vascular access (such as a double-lumen dialysis catheter) or permanent vascular access (arteriovenous or venovenous shunt) via a blood pump. Blood flow rates are graduated, depending upon the clinical condition of the patient. Efficient drug removal occurs with blood flow rates of approximately 300",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Pressure gauges detect interior rises in pressure, which indicate clot formation occurring inside the device; this is rare if heparinization is controlled via adequate monitoring of the ACT. If required, the procedure can be combined with hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/7/115?source=see_link\">",
"     \"Overview of the hemodialysis apparatus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoperfusion is usually performed for approximately four hours. Reuse of devices is not performed since partial saturation of small devices can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CRITERIA FOR CONSIDERATION OF HEMOPERFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, hemoperfusion should only be employed in the setting of intoxication with a drug or poison that can be removed at a rate that exceeds endogenous elimination by the liver or kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/17\">",
"     17",
"    </a>",
"    ]. Among patients who are poisoned, hemoperfusion should be used in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive deterioration despite intensive supportive therapy",
"     </li>",
"     <li>",
"      Severe intoxication with depression of midbrain function, thereby leading to hypoventilation, hypothermia, and hypotension",
"     </li>",
"     <li>",
"      Development of complications of coma, such as pneumonia or septicemia, as well as the presence of underlying conditions that predispose to such complications (eg, obstructive airway disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemoperfusion should also be considered in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impairment of normal drug excretory function due to hepatic, cardiac, or renal insufficiency.",
"     </li>",
"     <li>",
"      Intoxication with agents with metabolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delayed effects, such as mushrooms and paraquat. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Efficacy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hepatic failure, in which the extraction of hepatic toxins by hemoperfusion may prevent or delay hepatic coma and serve as a bridge to hepatic transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. However, some clinicians consider hemoperfusion to be unhelpful in this setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=see_link\">",
"       \"Acute liver failure in adults: Management and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      End-stage renal disease with aluminum intoxication; hemoperfusion has been used in conjunction with chelating agents (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      ) to remove aluminum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/21\">",
"       21",
"      </a>",
"      ]. Hemofiltration using charcoal hemoperfusion doubles the rate of removal of the deferoxamine-aluminum chelate compared with standard hemodialysis membranes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. However, given the necessity for roughly one year of therapy, the most economical alternative is the use and reuse of a high flux hemodialyzer rather than the very expensive charcoal hemoperfusion cartridge. In acute aluminum poisoning, high flux dialysis (using deferoxamine as the chelating agent) was superior to that of charcoal hemoperfusion in removing aluminum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=see_link\">",
"       \"Aluminum toxicity in end-stage renal disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a poison is eliminated equally well with hemodialysis and hemoperfusion, hemodialysis is preferred since it will also correct a concurrent acid-base disturbance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/1\">",
"     1",
"    </a>",
"    ]. Additionally, there is generally greater expertise and availability with respect to hemodialysis than hemoperfusion. If necessary, hemoperfusion can be combined with hemodialysis for the correction of an acid-base disturbance or of low body temperature in the severely hypothermic patient.",
"   </p>",
"   <p>",
"    Experiments in humans suggest that regional hemoperfusion of blood draining a limb, the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/25\">",
"     25",
"    </a>",
"    ], or the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32581/abstract/26\">",
"     26",
"    </a>",
"    ] may significantly limit anticancer drug toxicity; regional use reduces systemic exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal intoxication models, hemoperfusion increases drug elimination rates of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/7/36982?source=see_link\">",
"     amobarbital",
"    </a>",
"    , ethchlorvynol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and digitoxin. In these animal models as well as clinical experience, it has been observed that \"rebound\" of drug concentration occurs following hemoperfusion.",
"   </p>",
"   <p>",
"    With \"rebound\", the drug redistributes from tissues into the plasma following its removal from the plasma compartment. This is consistent with the pharmacokinetic handling of drugs after their removal from the central compartment; the rebound in drug concentration in plasma may be clinically significant, including a return to severe neurologic dysfunction or coma (as with glutethimide poisoning).",
"   </p>",
"   <p>",
"    Intermittent hemoperfusion helps minimize this \"rebound\" effect (as with paraquat and glutethimide). An additional advantage of intermittent hemoperfusion is a reduction in the hematologic side effects of prolonged hemoperfusion (see below). Replacement of saturated devices with fresh devices is not usually necessary, but is another positive aspect of short intermittent hemoperfusion.",
"   </p>",
"   <p>",
"    Not unexpectedly, a review of pharmacokinetic data reveals that hemodialysis and hemoperfusion enhance drug elimination only for specific drugs. In humans, in view of the difficulties in conducting controlled prospective clinical trials, a reduction in coma-time or overall mortality has not been conclusively demonstrated, although it has been suggested by retrospective studies.",
"   </p>",
"   <p>",
"    Table 2 shows representative drug extraction ratios (amount of drug removed relative to one) for many drugs (",
"    <a class=\"graphic graphic_table graphicRef62301 \" href=\"mobipreview.htm?42/15/43259\">",
"     table 2",
"    </a>",
"    ). The extraction ratios for many drugs are greater with hemoperfusion than with cuprophane hemodialysis, although high-flux membranes may offer an alternative and similar performance. Table 3 lists some chemicals and drugs removed by various types of hemoperfusion (",
"    <a class=\"graphic graphic_table graphicRef52887 \" href=\"mobipreview.htm?7/41/7838\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important side effect of hemoperfusion with charcoal or resin preparations is platelet depletion. An average loss of 30 percent of platelets with coated or uncoated charcoal or resin occurs; the reduced platelet count usually returns to normal within 24 to 48 hours following a single hemoperfusion. Greater degrees of thrombocytopenia are observed with resin than with charcoal.",
"   </p>",
"   <p>",
"    Other side effects of hemoperfusion are hypocalcemia, hypoglycemia, and a transient fall in white blood cell count; these complications are usually minor, and correct spontaneously or can be corrected. There is also a mild reduction of one to two degrees in body temperature.",
"   </p>",
"   <p>",
"    Hypotension is infrequent. If needed, vasopressor agents should be administered distal to the sorbent devices to minimize their adsorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7169304\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoperfusion consists of the passage of anticoagulated blood through a device containing adsorbent particles. The type of adsorbent particle utilized within a hemoperfusion device may vary. The most commonly available particles are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      and resin. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, hemoperfusion is preferred to hemodialysis for the removal of chemicals that are lipid soluble or are highly protein bound. Hemodialysis is preferred for water-soluble low molecular weight compounds. However the advantage of hemoperfusion over cuprophane dialyzers has lessened with the advent of high flux dialysis membranes. If a poison is eliminated equally well with hemodialysis and hemoperfusion, hemodialysis is preferred since it will also correct a concurrent acid-base disturbance. Additionally, there is generally greater expertise and availability with respect to hemodialysis than hemoperfusion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physical principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Criteria for consideration of hemoperfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, hemoperfusion should only be employed in the setting of intoxication with a drug or poison that can be removed at a rate that exceeds endogenous elimination by the liver or kidney. Among patients who are poisoned, hemoperfusion should be considered in patients who demonstrate progressive deterioration despite intensive supportive therapy; those with severe intoxication with depression of midbrain function, leading to hypoventilation, hypothermia, and hypotension; and in the setting of development of complications of coma, such as pneumonia or septicemia, or underlying conditions that predispose to such complications (eg, obstructive airway disease). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Criteria for consideration of hemoperfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemoperfusion may also be considered when there is impairment of normal drug excretory function due to hepatic, cardiac, or renal insufficiency; when there is intoxication with agents with metabolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delayed effects, such as mushrooms and paraquat; and in patients with end-stage renal disease with aluminum intoxication. Hemoperfusion may be used in the setting of hepatic failure to prevent or delay hepatic coma and serve as a bridge to hepatic transplantation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Criteria for consideration of hemoperfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Platelet depletion is the most important side effect of hemoperfusion. Other side effects include hypocalcemia, hypoglycemia, a transient fall in white blood cell count, and a mild reduction in body temperature. Hypotension is infrequent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Winchester, JF, Boldur, A, Oleru, C, Kitiyakara, C. Use of dialysis and hemoperfusion in treatment of poisoning. In: Handbook of Dialysis, 4th ed, Daugirdas, JT, Blake, PG, Ing, TS (Eds), Lippincott Willliams &amp; Wilkins, Philadelphia 2007. p. 300.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/2\">",
"      Muirhead, EE, Reid, AF. Resin artificial kidney. Lab Clin Med 1948; 33:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/3\">",
"      Hampel G, Crome P, Widdop B, Goulding R. Experience with fixed-bred charcoal haemoperfusion in the treatment of severe drug intoxication. Arch Toxicol 1980; 45:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/4\">",
"      Gelfand MC, Winchester JF, Knepshield JH, et al. Treatment of severe drug overdosage with charcoal hemoperfusion. Trans Am Soc Artif Intern Organs 1977; 23:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/5\">",
"      Verpooten GA, De Broe ME. Combined hemoperfusion-hemodialysis in severe poisoning: kinetics of drug extraction. Resuscitation 1984; 11:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/6\">",
"      Shalkham AS, Kirrane BM, Hoffman RS, et al. The availability and use of charcoal hemoperfusion in the treatment of poisoned patients. Am J Kidney Dis 2006; 48:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/7\">",
"      Terman DS, Buffaloe G, Mattioli C, et al. Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet 1979; 2:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/8\">",
"      Ault A. New direction for treatment of rheumatoid arthritis offered in USA. Lancet 1999; 353:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/9\">",
"      Caldwell J, Gendreau RM, Furst D, et al. A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis. J Rheumatol 1999; 26:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/10\">",
"      Hakim RM, Milford E, Himmelfarb J, et al. Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis 1990; 16:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/11\">",
"      Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/12\">",
"      Denti E, Luboz MP, Tessore V. Adsorption characteristics of cellulose acetate coated charcoals. J Biomed Mater Res 1975; 9:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/13\">",
"      Winchester JF. Dialysis and hemoperfusion in poisoning. Adv Ren Replace Ther 2002; 9:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/14\">",
"      Koh KH, Tan HH. High-flux haemodialysis treatment as treatment for carbamazepine intoxication. Med J Malaysia 2006; 61:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/15\">",
"      Tapolyai M, Campbell M, Dailey K, Udvari-Nagy S. Hemodialysis is as effective as hemoperfusion for drug removal in carbamazepine poisoning. Nephron 2002; 90:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/16\">",
"      Palmer BF. Effectiveness of hemodialysis in the extracorporeal therapy of phenobarbital overdose. Am J Kidney Dis 2000; 36:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/17\">",
"      Maher, JF, Schreiner, GE. The dialysis of poison and drugs. Trans Am Soc Artif Intern Organ 1967; 13:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/18\">",
"      McCarthy M, Ellis AJ, Wendon JA, et al. Use of extracorporeal liver assist device and auxiliary liver transplantation in fulminant hepatic failure. Eur J Gastroenterol Hepatol 1997; 9:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/19\">",
"      Kaplan AA, Epstein M. Extracorporeal blood purification in the management of patients with hepatic failure. Semin Nephrol 1997; 17:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/20\">",
"      O'Grady JG, Gimson AE, O'Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/21\">",
"      Chang TM, Barre P. Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis. Lancet 1983; 2:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/22\">",
"      Molitoris BA, Alfrey AC, Alfrey PS, Miller NL. Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers. Kidney Int 1988; 34:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/23\">",
"      Weiss LG, Danielson BG, Fellstr&ouml;m B, Wikstr&ouml;m B. Aluminum removal with hemodialysis, hemofiltration and charcoal hemoperfusion in uremic patients after desferrioxamine infusion. A comparison of efficiency. Nephron 1989; 51:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/24\">",
"      Bouchard, NC, Malostovsker, I, Harbord, N, et al. Acute Encephalopathy: Aluminum Extraction with High-Flux Dialysis is Superior to Charcoal Hemoperfusion. Clin Toxicol 2005; 43:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/25\">",
"      Iwasaki T, Ku Y, Kusunoki N, et al. Regional pharmacokinetics of doxorubicin following hepatic arterial and portal venous administration: evaluation with hepatic venous isolation and charcoal hemoperfusion. Cancer Res 1998; 58:3339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32581/abstract/26\">",
"      Oldfield EH, Dedrick RL, Yeager RL, et al. Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage. J Neurosurg 1985; 63:726.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1901 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32581=[""].join("\n");
var outline_f31_52_32581=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7169304\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSICAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEMOPERFUSION METHODOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CRITERIA FOR CONSIDERATION OF HEMOPERFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7169304\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1901\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1901|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/61/3035\" title=\"table 1\">",
"      Hemoperfusion devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/15/43259\" title=\"table 2\">",
"      Extraction ratios HP and HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/41/7838\" title=\"table 3\">",
"      Drugs removed with HP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34570?source=related_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38120?source=related_link\">",
"      Hemodialysis anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/7/115?source=related_link\">",
"      Overview of the hemodialysis apparatus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_52_32582="Large volume thoracentesis";
var content_f31_52_32582=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Large volume thoracentesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32582/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32582/contributors\">",
"     John T Huggins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32582/contributors\">",
"     Peter Doelken, MD, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32582/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32582/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32582/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32582/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/52/32582/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25574975\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large volume thoracentesis refers to the removal of more than one liter of pleural fluid during a therapeutic thoracentesis. Large volume thoracentesis is performed to relieve dyspnea associated with a pleural effusion. Assessment of the initial pleural fluid pressure and the changes in pressure as fluid is removed (known as the pleural space elastance) can be used to guide fluid removal.",
"   </p>",
"   <p>",
"    The technique for large volume thoracentesis will be reviewed here. The diagnostic evaluation of pleural fluid and the techniques for pleural manometry and diagnostic thoracentesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4534?source=see_link\">",
"     \"Measurement of pleural pressure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=see_link\">",
"     \"Diagnostic thoracentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2632?source=see_link\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25574982\">",
"    <span class=\"h1\">",
"     DEFINITIONS AND NORMAL VALUES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large volume thoracentesis refers to removal of more than 1L of pleural fluid during a therapeutic thoracentesis.",
"     </li>",
"     <li>",
"      Pleural elastance is the change in pleural pressure with removal of a given volume of pleural fluid. It is calculated by dividing the change in pleural pressure by the volume removed. A normal pleural elastance is estimated to be &lt;14.5 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4534?source=see_link&amp;anchor=H934433#H934433\">",
"       \"Measurement of pleural pressure\", section on 'Pleural elastance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The initial pleural pressure of a free-flowing pleural effusion with an expandable lung is typically slightly positive (pleural pressure in the absence of fluid is slightly negative) and changes minimally as fluid is withdrawn. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4534?source=see_link&amp;anchor=H933974#H933974\">",
"       \"Measurement of pleural pressure\", section on 'Interpretation of pleural pressures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the lung is unable to expand as fluid is withdrawn from the pleural space, the pleural pressure decreases. With lung entrapment, the pressure decreases gradually as fluid is withdrawn, culminating in a steep decrease in pressure when minimal fluid remains in the pleural space. In the presence of trapped lung, a rapid decrease in pleural pressure occurs as fluid is withdrawn (eg, to &lt;-20 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O), correlating with a pleural elastance greater than 14.5 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L",
"      </span>",
"      (often greater than 25 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef59718 \" href=\"mobipreview.htm?13/11/13502\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4534?source=see_link&amp;anchor=H933974#H933974\">",
"       \"Measurement of pleural pressure\", section on 'Interpretation of pleural pressures'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25575598\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indication for large volume thoracentesis is dyspnea due to a moderate to large pleural effusion confirmed by physical examination and chest radiography.",
"   </p>",
"   <p>",
"    Anticoagulation and bleeding diatheses are relative contraindications to large volume thoracentesis. Other potential contraindications to thoracentesis are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic thoracentesis\", section on 'Contraindications'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Pleural effusions due to trapped lung and transudative effusions due to liver failure are not managed with large volume thoracentesis, although an initial large volume thoracentesis may occasionally be necessary for relief of dyspnea in patients with hepatic hydrothorax. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4072?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and management of pleural causes of unexpandable lung\", section on 'Trapped lung'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30263?source=see_link&amp;anchor=H5#H5\">",
"     \"Hepatic hydrothorax\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25575605\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians who perform thoracentesis should have experience and demonstrated competency with the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient&rsquo;s identity and planned procedure are confirmed, and the side of the thorax to be accessed is confirmed by physical examination and review of the chest radiograph. The procedure should be explained in detail to the patient and informed consent obtained. The correct procedure for site preparation, local anesthesia, and placement of the thoracentesis catheter in the pleural space is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnostic thoracentesis\", section on 'Technique'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26408?source=see_link&amp;anchor=H543573657#H543573657\">",
"     \"Thoracic ultrasound: Indications, advantages, and technique\", section on 'Identification of pleural fluid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The equipment needed for large volume thoracentesis with measurement of pleural pressures is listed in the table (",
"    <a class=\"graphic graphic_table graphicRef83425 \" href=\"mobipreview.htm?19/7/19579\">",
"     table 1",
"    </a>",
"    ). The apparatus for measurement of pleural pressure is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4534?source=see_link&amp;anchor=H25576496#H25576496\">",
"     \"Measurement of pleural pressure\", section on 'Equipment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In order to measure pleural pressures and elastance at the time of thoracentesis, the patient should be in an upright sitting position with his or her arms resting on a surface such as a bedside table. When available, thoracic ultrasound is employed to confirm the location of the pleural effusion and select a dependent portion that is above the level of the diaphragm through all phases of the respiratory cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The exact puncture site should be immediately above the superior aspect of a rib to avoid the neurovascular bundle and, when possible, 8 to 10 cm lateral to the spine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26408?source=see_link&amp;anchor=H543573657#H543573657\">",
"     \"Thoracic ultrasound: Indications, advantages, and technique\", section on 'Identification of pleural fluid'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=see_link&amp;anchor=H1913760#H1913760\">",
"     \"Diagnostic thoracentesis\", section on 'Avoidance of intercostal arteries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Without moving the patient, a wide area surrounding the puncture site is sterilized with 0.05 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    &nbsp;or 10 percent povidone-iodine solution, and sterile drapes are placed around the site. Local anesthetic (eg, 1 or 2 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) is administered to the site as for diagnostic thoracentesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnostic thoracentesis\", section on 'Site preparation and local anesthesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A thoracentesis catheter (eg, 8 French catheter over an 18-gauge 7.5 inch [19 cm] needle) with a 50 mL syringe attached via a stopcock is inserted, advanced to the rib, and then moved cephalad by 1 to 2 mm increments until the catheter can be advanced up and over the superior edge of the rib. As the needle is advanced, aspiration is attempted by intermittently pulling back on the plunger of the syringe approximately every 2 to 3 mm. When pleural fluid is returned, the catheter is passed through the needle into the pleural space and the needle withdrawn from the skin. A sample of 50 to 60 mL of pleural fluid is obtained as needed for diagnostic testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnostic thoracentesis\", section on 'Specimen preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial pleural pressure measurement is obtained after removal of the sample for diagnostic testing (",
"    <a class=\"graphic graphic_figure graphicRef69925 \" href=\"mobipreview.htm?3/54/3939\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58189 \" href=\"mobipreview.htm?20/49/21268\">",
"     picture 1",
"    </a>",
"    ). Subsequent measurements of pleural pressure are obtained and recorded after each aliquot (eg, 100 to 250 mL) of pleural fluid is removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/5\">",
"     5",
"    </a>",
"    ]. We typically remove fluid using a syringe and tubing connected via a stopcock to a collection bag, rather than vacuum bottles, to avoid local application of excess negative pressure to an area of the pleura and to allow removal of more exact volumes of pleural fluid (",
"    <a class=\"graphic graphic_figure graphicRef69925 \" href=\"mobipreview.htm?3/54/3939\">",
"     figure 2",
"    </a>",
"    ). The measurement and interpretation of pleural pressures are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4534?source=see_link&amp;anchor=H933967#H933967\">",
"     \"Measurement of pleural pressure\", section on 'Technique'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25575612\">",
"    <span class=\"h1\">",
"     DETERMINING THE VOLUME OF FLUID TO BE REMOVED",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maximum volume of fluid that can be safely removed during therapeutic thoracentesis is uncertain because the occurrence of re-expansion pulmonary edema and procedure-related pneumothorax do not clearly correlate with the onset of symptoms or the volume of fluid removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. A traditional method to avoid these complications has been to discontinue fluid removal at the onset of chest discomfort or when the total amount of fluid removed reaches 1000 to 1500 mL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/3\">",
"     3",
"    </a>",
"    ]. However, this practice does not always prevent adverse effects, and many patients do well with removal of more than 1500 mL.",
"   </p>",
"   <p>",
"    An alternative method, which we prefer, combines symptom monitoring with serial measures of pleural pressure to determine a &ldquo;safe&rdquo; volume of fluid to remove; fluid removal is stopped if the patient develops chest discomfort or becomes hypotensive, if no more fluid can be aspirated, or if the pleural pressure decreases to less than -20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/1,3,7-10\">",
"     1,3,7-10",
"    </a>",
"    ]. Evidence in favor of this method comes from the following observations: (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4534?source=see_link&amp;anchor=H934253#H934253\">",
"     \"Measurement of pleural pressure\", section on 'Pressure measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The onset of vague chest discomfort correlates with development of more negative pleural pressures and is a sign that fluid removal should be discontinued [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/10\">",
"       10",
"      </a>",
"      ]. In a series of 169 patients, onset of chest discomfort was associated with lower (more negative) closing pressures and a greater total change in pleural pressure, while cough did not correlate with lower pressures or the change in pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/10\">",
"       10",
"      </a>",
"      ]. Among those who developed chest discomfort, only 22 percent had a potentially unsafe decrease in pleural pressure, suggesting that stopping fluid removal at the onset of chest discomfort avoided &ldquo;unsafe&rdquo; pleural pressures in the majority. Measuring pleural fluid pressure during thoracentesis (pleural manometry) provides an objective method to monitor the safety and benefit of ongoing fluid removal. Based on animal studies and observational studies in patients, the more negative the pleural pressure after fluid removal, the greater the risk of complications such as re-expansion pulmonary edema or post-procedure pneumothorax [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/1,8,9\">",
"       1,8,9",
"      </a>",
"      ]. In a series of 185 large volume thoracenteses, pleural fluid pressure was monitored and fluid removal stopped at the onset of chest discomfort or a pleural pressure of less than -20 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/9\">",
"       9",
"      </a>",
"      ]. The mean amount of fluid removed was 1670 mL and the range 1000 to 6550 mL. Only one patient developed significant re-expansion pulmonary edema, lending support to the value of monitoring pleural pressure during large volume thoracentesis. (See",
"      <a class=\"local\" href=\"#H25575633\">",
"       'Complications'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a patient experiences persistent chest discomfort that is believed due to negative pleural pressure and not a pneumothorax, we typically introduce ambient air (eg, 10 to 20 mL aliquots until discomfort relieved) into the pleural space. This usually relieves the discomfort immediately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25575626\">",
"    <span class=\"h1\">",
"     ASSESSMENT AFTER FLUID REMOVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postprocedural ultrasound or radiographic imaging is performed to determine whether a pneumothorax has developed and the amount of residual pleural fluid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26408?source=see_link&amp;anchor=H165837042#H165837042\">",
"     \"Thoracic ultrasound: Indications, advantages, and technique\", section on 'Identification of pneumothorax'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a pleural pressure at the end of thoracentesis that is &lt;-20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O or an abnormally high elastance (&gt;14.5 cm",
"    <span class=\"nowrap\">",
"     H",
"     <sub>",
"      2",
"     </sub>",
"     O/L),",
"    </span>",
"    an air contrast computed tomography scan of the chest is sometimes obtained to verify the presence of visceral pleural thickening as a cause of trapped lung physiology. The technique of air contrast computed tomography of the pleura is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4072?source=see_link&amp;anchor=H25147598#H25147598\">",
"     \"Diagnosis and management of pleural causes of unexpandable lung\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25578795\">",
"    <span class=\"h1\">",
"     EFFECT ON PULMONARY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of improvement in pulmonary function following large volume thoracentesis does not correlate well with the volume of fluid withdrawn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/11\">",
"     11",
"    </a>",
"    ]. In a series of 26 thoracenteses, the improvement in the forced vital capacity (FVC) was small relative to the amount of fluid withdrawn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/11\">",
"     11",
"    </a>",
"    ]. After the removal of 800 mL pleural fluid, patients with higher (less negative) pleural pressures and those with smaller decreases in the pleural pressure had greater improvements in their pulmonary functions after thoracentesis. This observation suggests that patients with more negative pleural pressure had unexpandable lung that limited the benefit of fluid removal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Lung volumes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25575633\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications associated with large volume thoracentesis include those associated with diagnostic thoracentesis, as well as an increased risk of re-expansion pulmonary edema and postprocedure pneumothorax. The complications common to diagnostic thoracentesis (eg, pain at the puncture site, bleeding, pneumothorax, empyema, soft tissue infection, spleen or liver puncture, vasovagal events, seeding the needle tract with tumor, and adverse reactions to the anesthetic or topical antiseptic solutions) are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnostic thoracentesis\", section on 'Complications'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25578838\">",
"    <span class=\"h2\">",
"     Re-expansion pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Re-expansion pulmonary edema is a type of noncardiogenic pulmonary edema that occurs after re-expansion of the lung following drainage of a moderate to large pneumothorax or pleural effusion. The mechanisms by which re-expansion pulmonary edema can occur are complex and controversial. These mechanisms could include a direct injury due to reperfusion or indirect mechanisms that are mechanical in nature. The indirect mechanisms may include: (1) surfactant dysfunction in chronic atelectatic lung; and (2) increased transpleural pressures when excessively negative pleural pressures are created during fluid removal in the setting of an unexpandable lung.",
"   </p>",
"   <p>",
"    Symptomatic re-expansion pulmonary edema is an uncommon complication of large volume thoracentesis, occurring in less than 1 percent, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/12-15\">",
"     12-15",
"    </a>",
"    ], while asymptomatic radiographic evidence of pulmonary edema (eg, diffuse ground glass opacities usually on the side of the thoracentesis) is slightly more common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. Symptomatic and radiographic resolution typically occurs over 24 to 48 hours. Management is largely supportive with supplemental oxygen and cardiopulmonary monitoring. The diagnosis and management of re-expansion pulmonary edema are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=see_link&amp;anchor=H14#H14\">",
"     \"Noncardiogenic pulmonary edema\", section on 'Reexpansion pulmonary edema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25578845\">",
"    <span class=\"h2\">",
"     Postprocedure pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of postprocedure pneumothorax increases with the volume of fluid withdrawn, although some patients appear to tolerate larger volumes of fluid removal than others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. Compared to a thoracentesis of 0.8-1.2 L, drainage of 1.8-2.2 L was associated with a more than threefold increase in risk for pneumothorax (odds ratio [OR] 3.8, 95% CI 1.28-11.2), and after drainage of 2.3 L or more, the increase in risk was almost sixfold (OR 5.7, 95% CI 1.30-24.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/17\">",
"     17",
"    </a>",
"    ]. The specific causes of pneumothorax complicating large volume thoracentesis include iatrogenic lung puncture, inadvertent introduction of air during the procedure, and pneumothorax ex vacuo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25578852\">",
"    <span class=\"h2\">",
"     Pneumothorax ex vacuo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax ex vacuo refers to the development of a pneumothorax due to strongly negative pleural pressure created during pleural fluid removal. The causes of pneumothorax ex vacuo are attributed to an unexpandable lung and include chronic atelectasis, endobronchial obstruction, and visceral pleural restriction due to either a trapped lung or lung entrapment. The negative pleural pressure is thought to draw air from the lung across the visceral pleura and into the pleural space without a discrete puncture of the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of pneumothorax ex vacuo was evaluated in a series of 265 patients who underwent ultrasound-guided therapeutic thoracentesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32582/abstract/1\">",
"     1",
"    </a>",
"    ]. Careful attention to selection of the insertion site was employed to avoid puncturing lung parenchyma, and proper technique was used to avoid entrance of air into the pleural cavity via the procedure tubing or wound. Eight unintentional, atraumatic pneumothoraces were associated with radiographic evidence of unexpandable lung and decreasing pleural pressures with drainage, but not excessively negative pleural pressures. It is hypothesized that a transient, pressure-related parenchymal-pleural fistula develops due to shear forces created during nonuniform re-expansion of unexpandable lung (eg, trapped or entrapped lung). The observation of high pleural elastance in several cases supports the hypothesis.",
"   </p>",
"   <p>",
"    Of note, postprocedure radiographs of a pneumothorax ex vacuo may show ipsilateral volume loss (rather than an unchanged or increased volume of the hemithorax), and the pneumothorax may be located at the base of the lung in the area where pleural fluid was withdrawn. Small, asymptomatic postprocedure pneumothoraces can usually be managed conservatively with observation. Tube thoracostomy should be considered if the pneumothorax is large, progressive, the patient is symptomatic, or the patient is mechanically ventilated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumothorax ex vacuo can usually be avoided by using pleural manometry to guide fluid removal; fluid withdrawal is stopped if the pleural pressure is more negative than -20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O, or the pleural elastance exceeds 14.5 cm",
"    <span class=\"nowrap\">",
"     H",
"     <sub>",
"      2",
"     </sub>",
"     O/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4534?source=see_link&amp;anchor=H934433#H934433\">",
"     \"Measurement of pleural pressure\", section on 'Pleural elastance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25576154\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large volume thoracentesis refers to the removal of 1 L or more of pleural fluid. The indication for large volume thoracentesis is dyspnea due to a moderate to large pleural effusion confirmed by physical examination and chest radiography. Relative contraindications include anticoagulation and bleeding diatheses. Pleural effusions due to trapped lung or liver failure are not managed with large volume thoracentesis. (See",
"      <a class=\"local\" href=\"#H25575598\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of complications from large volume thoracentesis correlates imperfectly with the volume of fluid removed. When performing large volume thoracentesis, complication rates can be reduced if fluid removal is stopped when the patient develops chest discomfort, the pleural pressure decreases to less than -20 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O, the pleural elastance is greater than 14.5 cm",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/L,",
"      </span>",
"      or no more fluid can be aspirated. In the absence of pleural manometry, fluid removal is stopped at the onset of chest discomfort or when the total amount of fluid removed reaches 1000 to 1500 mL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4534?source=see_link&amp;anchor=H934253#H934253\">",
"       \"Measurement of pleural pressure\", section on 'Pressure measurement'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H25575612\">",
"       'Determining the volume of fluid to be removed'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postprocedural ultrasound or radiographic imaging is performed to determine whether a pneumothorax has developed and to assess the amount of residual pleural fluid. (See",
"      <a class=\"local\" href=\"#H25575626\">",
"       'Assessment after fluid removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic re-expansion pulmonary edema is an uncommon complication of large volume thoracentesis, occurring in less than 1 percent. Resolution typically occurs over 24 to 48 hours. Management is largely supportive with supplemental oxygen and cardiopulmonary monitoring. (See",
"      <a class=\"local\" href=\"#H25575633\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=see_link&amp;anchor=H14#H14\">",
"       \"Noncardiogenic pulmonary edema\", section on 'Reexpansion pulmonary edema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The specific causes of pneumothorax following large volume thoracentesis include iatrogenic lung puncture, inadvertent introduction of air during the procedure, and ingress of air via pleuro-parenchymal fistula(e) caused by negative intrapleural pressure or, possibly, shear forces during lung re-expansion. (See",
"      <a class=\"local\" href=\"#H25575633\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other potential complications of large volume thoracentesis include pain at the puncture site, bleeding, pneumothorax, empyema, soft tissue infection, spleen or liver puncture, vasovagal events, seeding the needle tract with tumor, and adverse reactions to the anesthetic or topical antiseptic solutions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=see_link&amp;anchor=H10#H10\">",
"       \"Diagnostic thoracentesis\", section on 'Complications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/1\">",
"      Heidecker J, Huggins JT, Sahn SA, Doelken P. Pathophysiology of pneumothorax following ultrasound-guided thoracentesis. Chest 2006; 130:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/2\">",
"      Daniels CE, Ryu JH. Improving the safety of thoracentesis. Curr Opin Pulm Med 2011; 17:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/3\">",
"      Havelock T, Teoh R, Laws D, et al. Pleural procedures and thoracic ultrasound: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/4\">",
"      Duncan DR, Morgenthaler TI, Ryu JH, Daniels CE. Reducing iatrogenic risk in thoracentesis: establishing best practice via experiential training in a zero-risk environment. Chest 2009; 135:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/5\">",
"      Huggins JT, Doelken P. Pleural manometry. Clin Chest Med 2006; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/6\">",
"      Gordon CE, Feller-Kopman D, Balk EM, Smetana GW. Pneumothorax following thoracentesis: a systematic review and meta-analysis. Arch Intern Med 2010; 170:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/7\">",
"      Doelken P, Huggins JT, Pastis NJ, Sahn SA. Pleural manometry: technique and clinical implications. Chest 2004; 126:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/8\">",
"      Light RW, Jenkinson SG, Minh VD, George RB. Observations on pleural fluid pressures as fluid is withdrawn during thoracentesis. Am Rev Respir Dis 1980; 121:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/9\">",
"      Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry. Curr Opin Pulm Med 2007; 13:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/10\">",
"      Feller-Kopman D, Walkey A, Berkowitz D, Ernst A. The relationship of pleural pressure to symptom development during therapeutic thoracentesis. Chest 2006; 129:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/11\">",
"      Light RW, Stansbury DW, Brown SE. The relationship between pleural pressures and changes in pulmonary function after therapeutic thoracentesis. Am Rev Respir Dis 1986; 133:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/12\">",
"      Mynarek G, Brabrand K, Jakobsen JA, Kolbenstvedt A. Complications following ultrasound-guided thoracocentesis. Acta Radiol 2004; 45:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/13\">",
"      Jones PW, Moyers JP, Rogers JT, et al. Ultrasound-guided thoracentesis: is it a safer method? Chest 2003; 123:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/14\">",
"      Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 2007; 84:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/15\">",
"      Lin YJ, Yu YH. Reexpansion pulmonary edema after large-volume thoracentesis. Ann Thorac Surg 2011; 92:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/16\">",
"      Tarver RD, Broderick LS, Conces DJ Jr. Reexpansion pulmonary edema. J Thorac Imaging 1996; 11:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/17\">",
"      Josephson T, Nordenskjold CA, Larsson J, et al. Amount drained at ultrasound-guided thoracentesis and risk of pneumothorax. Acta Radiol 2009; 50:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32582/abstract/18\">",
"      Woodring JH, Baker MD, Stark P. Pneumothorax ex vacuo. Chest 1996; 110:1102.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17172 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32582=[""].join("\n");
var outline_f31_52_32582=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25576154\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25574975\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25574982\">",
"      DEFINITIONS AND NORMAL VALUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25575598\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25575605\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25575612\">",
"      DETERMINING THE VOLUME OF FLUID TO BE REMOVED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25575626\">",
"      ASSESSMENT AFTER FLUID REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25578795\">",
"      EFFECT ON PULMONARY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25575633\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25578838\">",
"      Re-expansion pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25578845\">",
"      Postprocedure pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25578852\">",
"      Pneumothorax ex vacuo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25576154\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/17172\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/17172|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/11/13502\" title=\"figure 1\">",
"      Pleural pressure volume curve in trapped lung and heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/54/3939\" title=\"figure 2\">",
"      Water manometer for pleural pressure measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/17172|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/49/21268\" title=\"picture 1\">",
"      Water manometer for pleural pressure measurement 22G needle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/17172|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/7/19579\" title=\"table 1\">",
"      Equipment for pleural manometry",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4072?source=related_link\">",
"      Diagnosis and management of pleural causes of unexpandable lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2632?source=related_link\">",
"      Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=related_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30263?source=related_link\">",
"      Hepatic hydrothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4534?source=related_link\">",
"      Measurement of pleural pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26408?source=related_link\">",
"      Thoracic ultrasound: Indications, advantages, and technique",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_52_32583="B virus infection";
var content_f31_52_32583=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32583/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32583/contributors\">",
"     Jeffrey I Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32583/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32583/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32583/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32583/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/52/32583/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;B virus (Cercopithecine herpesvirus 1) causes a herpes simplex virus (HSV)-like infection in macaque monkeys, but can also cause a fatal encephalomyelitis in humans. Fatal cases of B virus infection have been reported after exposures to monkey bites, monkey scratches, cage scratches, a mucosal splash from monkey material, and from infected cell cultures. Postexposure prophylaxis has been demonstrated to be effective in an animal model and is likely effective in humans exposed to the virus. Prompt therapy for B virus infection of humans is critical to prevent severe morbidity and mortality.",
"   </p>",
"   <p>",
"    The pathogenesis, epidemiology, clinical manifestations, prognosis, prevention, postexposure prophylaxis, and treatment of B virus infection will be reviewed here. Infections caused by other zoonoses are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26986?source=see_link\">",
"     \"Zoonoses from pets other than dogs and cats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31401?source=see_link\">",
"     \"Zoonoses from cats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/24/29065?source=see_link\">",
"     \"Zoonoses from dogs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Natural infection in macaques",
"    </span>",
"    &nbsp;&mdash;&nbsp;B virus is a herpesvirus in the same subfamily as herpes simplex virus (HSV) that naturally infects macaque monkeys (eg, rhesus macaques, cynomolgus monkeys, pig-tailed macaques, bonnet macaques, Japanese macaques, and stump-tail macaques) and usually results in either no symptoms in these animals or oral or genital lesions similar to HSV in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. B virus has not been detected in other Old World monkeys or in New World monkeys.",
"   </p>",
"   <p>",
"    Macaques become latently infected and virus is shed lifelong in oral and genital secretions and from the conjunctivae, including when animals are asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complete sequence of the virus has been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infection of humans",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of B virus infections in humans has occurred in individuals who work with nonhuman primates. Humans become infected after exposure to oral, genital, or ocular secretions or central nervous system tissue from macaque monkeys. Of 26 well-documented cases of B virus infection in humans, 10 cases were due to monkey bites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/5,6\">",
"     5,6",
"    </a>",
"    ] and two each were due to monkey scratches, monkey cage scratches, needlestick injuries, or possible aerosols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]. One of the needlestick injuries was from a needle used to inject tissues around the eye of an animal, and may have been contaminated with infected ocular secretions. Exposure to monkey blood has not been reported to cause B virus disease in humans. One of the possible aerosol exposures was thought to occur during autopsy of a monkey.",
"   </p>",
"   <p>",
"    Case reports include a mucosal splash in which a woman died after material from a monkey splashed into her eye [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/8\">",
"     8",
"    </a>",
"    ], person-to-person transmission in which a woman became infected after applying glucocorticoid cream to her husband's vesicular B virus lesion and then to her contact dermatitis lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/9\">",
"     9",
"    </a>",
"    ], a laceration from a tissue culture bottle used to grow monkey cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/10\">",
"     10",
"    </a>",
"    ], contamination of a wound with monkey saliva [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/11\">",
"     11",
"    </a>",
"    ], and cleaning a monkey skull [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/12\">",
"     12",
"    </a>",
"    ]. One case was thought to be due to reactivation of B virus; however, it is uncertain if this really was due to reactivation or an unappreciated recent exposure to the virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Travelers have the potential to be exposed to free-ranging monkeys that are seropositive for B virus, which are native in India, Indonesia, and Nepal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. In addition, monkeys that are seropositive for B virus have escaped from research institutes and are now free-ranging in certain locations such as Puerto Rico and other sites in the Caribbean [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/18\">",
"     18",
"    </a>",
"    ]. Macaques, including cynomolgus monkeys, have been kept as pets, some of which are seropositive for B virus, and this has the potential to be a source of transmission of virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the age and the health status of macaques contributes to the risk of transmitting B virus. Most animals more than 2.5 years old have been infected with B virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/20\">",
"     20",
"    </a>",
"    ]. Animals that are immunocompromised, ill, stressed, or have visible genital or oral lesions are more likely to shed B virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/3,5,21-24\">",
"     3,5,21-24",
"    </a>",
"    ]. Virus is shed from oral and genital secretions as well as from the conjunctivae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/3,21,23,24\">",
"     3,21,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since 20 to 100 percent of captive macaques are seropositive for B virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/3\">",
"     3",
"    </a>",
"    ] and approximately 2 percent of seropositive macaques shed B virus on a given day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/21\">",
"     21",
"    </a>",
"    ], it is estimated that 0.4 to 2 percent of contacts with macaques have the potential to transmit B virus to humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]. With the large number of exposures to macaques that occur each year, the observation that only about 50 cases of B virus have been reported in the literature indicates that the vast majority of B virus exposures in humans do not result in disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain types of exposures to macaques carry a higher risk of transmitting virus than others. Wounds involving the head or neck (in which the virus can be transmitted more rapidly to the central nervous system before the development of local symptoms), deep puncture wounds, and wounds that are not adequately cleaned are thought to pose the highest risk of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast, exposures that involve intact skin are not thought to pose a risk of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately five days to three weeks after an exposure (range two days to five weeks), patients present with one of three patterns of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vesicular or ulcerative lesions, tingling, pain, or itching at the site of exposure, and local lymphadenopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Influenza-like illness with fever and myalgias. Later symptoms may include numbness or paresthesias near the site of exposure, fever, conjunctivitis, abdominal pain, hepatitis, or pneumonitis followed by central nervous system (CNS) symptoms.",
"     </li>",
"     <li>",
"      Nausea and vomiting, and CNS symptoms including headache that may progress to meningismus, cranial nerve deficits, dysarthria, dysphagia, seizures, paralysis, respiratory failure, and coma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Asymptomatic infection of humans with B virus has not been documented. In a study of 321 primate workers, none of 166 persons with documented exposures to primates and none of the other 155 individuals were seropositive for B virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/26\">",
"     26",
"    </a>",
"    ]. In a second study, none of 116 asymptomatic primate workers tested during a cluster of B virus cases were seropositive for B virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/6\">",
"     6",
"    </a>",
"    ]. A third study found that none of 130 persons who either had contact with B virus-infected individuals or who were primate workers were seropositive for B virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of antiviral therapy, the mortality rate of B virus infection in humans was 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/1\">",
"     1",
"    </a>",
"    ]. It is estimated that 80 percent of individuals infected with B virus since the early 1980s have survived due to the availability of antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/1\">",
"     1",
"    </a>",
"    ]. To date, no cases have occurred in individuals who have received postexposure prophylaxis with antiviral medication within three days of B virus exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primate workers need to be appropriately educated about the risk of exposure to B virus, be knowledgeable about the importance of wound cleansing and first aid, have access to an eyewash, and have access to an occupational health care system that is knowledgeable about the virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]. Persons working with macaques should protect their eyes from mucosal splashes with either goggles or glasses that have side shields and either a chin length face shield or mask to protect their mouths from splashes. Body fluids from patients suspected of having B virus infection should be considered potentially infectious.",
"   </p>",
"   <p>",
"    Family members and health care workers should use blood and body fluid precautions to avoid exposure to B virus from infected individuals. B virus has been cultured from the oral mucosa and from skin lesions in a patient during intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POSTEXPOSURE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After injury to the skin and exposure to macaque fluids or tissues, the skin should be thoroughly washed as soon as possible with soap containing detergent such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    or briefly with a fresh 1:20 dilution of bleach (0.25 percent hypochlorite) followed by detergent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]. Exposed mucous membranes or eyes should be flushed with water or sterile saline. Washing of skin or mucous membranes should continue for 15 minutes.",
"   </p>",
"   <p>",
"    Evaluation by health care providers should include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether the individual was exposed to macaques or macaque body fluids or tissues.",
"     </li>",
"     <li>",
"      Determining the extent of the risk &mdash; Health of the primate, infection history of the primate (including retroviruses), type of exposure, site of exposure, time since exposure occurred.",
"     </li>",
"     <li>",
"      Assessment of the adequacy of cleansing, and if inadequate, initiate cleansing of the site of exposure.",
"     </li>",
"     <li>",
"      Assessment of the need for postexposure prophylaxis for B virus, rabies vaccination and immunoglobulin, tetanus vaccination, or antibiotic prophylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Examination of the exposure site.",
"     </li>",
"     <li>",
"      Consideration of diagnostic testing &mdash; Baseline serum from the exposed individual, viral culture at site of exposure after cleansing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Postexposure cultures and serology'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Education of the exposed individual regarding B virus and symptoms to watch for (eg, fever, myalgia, peripheral and central nervous system signs or symptoms).",
"     </li>",
"     <li>",
"      Ensure that the individual's supervisor and occupational health care provider are aware of the exposure.",
"     </li>",
"     <li>",
"      Ensure that the individual has a health care provider who can be seen for followup.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Postexposure cultures and serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;While some authorities believe that postcleansing cultures and serologies for B virus should be performed, others do not feel that these are necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]. Although positive cultures at the site of the exposure indicate that a true exposure to B virus occurred, cultures may be negative due to sampling error or removal of virus during cleansing. Obtaining cultures prior to cleansing is not recommended due to the risk of infection from delay of cleansing or from inoculation of virus deeper into the wound.",
"   </p>",
"   <p>",
"    There is even more uncertainty regarding the value of polymerase chain reaction (PCR) for B virus, since a positive result does not necessarily indicate infectious virus.",
"   </p>",
"   <p>",
"    Serology for B virus can be helpful in persons who have symptoms that are suggestive of B virus. Comparison of B virus serology three to six weeks after the exposure (or at the time of symptoms) with serology before or at the time of the exposure is especially helpful. For this reason, some occupational health centers obtain serologies on nonhuman primate workers before employment. A rise of &ge;4-fold in titer of paired sera tested concurrently is considered diagnostic of infection.",
"   </p>",
"   <p>",
"    For individuals who receive postexposure prophylaxis, seroconversion might be delayed and repeat testing should be considered approximately three months after exposure. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Postexposure prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cultures and serology in nonhuman primates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usefulness of B virus culture or serology in primates is even more uncertain than for exposed humans. A negative serology for B virus might occur in an animal early after primary infection, and a positive serology does not prove that the animal is shedding virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]. A negative culture may occur due to sampling error, and a positive culture from the animal does not prove that an exposed human was infected. Given the risk to primate workers of obtaining these samples and their limited usefulness, many authorities do not recommend obtaining these samples except in special circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diagnostic laboratories",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture, PCR, and serology for B virus in humans and nonhuman primates are performed in the United States by the B Virus Research and Resource Laboratory at Georgia State University in Atlanta, Georgia; phone: 404-651-0808; website:",
"    <a class=\"external\" href=\"file://www.gsu.edu/~wwwvir/index.html\">",
"     file://www.gsu.edu/~wwwvir/index.html",
"    </a>",
"    . Culture, PCR, and serology of nonhuman primates can also be performed in the United States by VRL Laboratories in San Antonio, Texas; phone 877-615-7275.",
"   </p>",
"   <p>",
"    Culture, PCR, and serology for B virus in humans and nonhuman primates are performed in the United Kingdom by the Virus Reference Department in London, United Kingdom; phone 020-8327-6017.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     POSTEXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A B Virus Working Group convened by the United States Centers for Disease Control and Prevention has published guidelines for the prevention and therapy of B virus infection for individuals who have had potential exposures to B virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]. Our recommendations for postexposure prophylaxis are consistent with these guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No studies of postexposure prophylaxis have been performed in humans; however, studies have been done using experimentally infected rabbits. Postexposure prophylaxis of rabbits using intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    three times daily for two weeks beginning one day after exposure was 100 percent effective in preventing B virus disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/28\">",
"     28",
"    </a>",
"    ]. Postexposure prophylaxis of rabbits with intravenous acyclovir for two weeks beginning five days after exposure was partially effective for preventing disease.",
"   </p>",
"   <p>",
"    In another study in rabbits, postexposure prophylaxis with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    was more effective than oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    at preventing development of B virus disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/29\">",
"     29",
"    </a>",
"    ]. In a dose escalation experiment, prophylaxis with oral ganciclovir dosed at 86 to 175",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for two weeks beginning one day after exposure was effective in preventing disease. In addition, prophylaxis with 170",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of oral ganciclovir for two weeks beginning five days after exposure resulted in survival of all animals. Postexposure prophylaxis with oral acyclovir given at 700",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three weeks beginning one day after exposure was 100 percent effective in preventing disease. However, disease developed when given at 500",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, although all the rabbits survived.",
"   </p>",
"   <p>",
"    Postexposure prophylaxis is recommended for high risk exposures to macaques if the exposure occurred within the prior five days (",
"    <a class=\"graphic graphic_table graphicRef55170 \" href=\"mobipreview.htm?16/2/16428\">",
"     table 1",
"    </a>",
"    ). These recommendations are based on the types of exposures that resulted in B virus disease in humans and the timing of postexposure prophylaxis found to be effective in the animal studies discussed above. Antiviral medication should be started as soon as possible after exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Indications for prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postexposure prophylaxis is recommended for individuals with the following types of exposures to macaque monkeys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin or mucosal exposures to animals that are at high risk of shedding B virus (ill or immunocompromised macaques, animals with oral or genital lesions, or animals known to be shedding virus)",
"     </li>",
"     <li>",
"      Inadequately cleaned skin or mucosal exposures",
"     </li>",
"     <li>",
"      Lacerations of the head, neck, or torso",
"     </li>",
"     <li>",
"      Deep puncture bites",
"     </li>",
"     <li>",
"      Needlestick injuries in which the needle was exposed to macaque tissue or fluid from the central nervous system (CNS), mucosa, or eyes",
"     </li>",
"     <li>",
"      Lacerations or puncture wounds with objects contaminated with macaque fluid from oral or genital lesions, CNS tissues, or known to contain B virus",
"     </li>",
"     <li>",
"      Exposures in which postcleansing cultures are positive for B virus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prophylaxis should be considered for some types of lower risk exposures (",
"    <a class=\"graphic graphic_table graphicRef55170 \" href=\"mobipreview.htm?16/2/16428\">",
"     table 1",
"    </a>",
"    ). Prophylaxis is",
"    <strong>",
"     not",
"    </strong>",
"    necessary for exposures of intact skin or exposures associated with non-macaque species of nonhuman primates.",
"   </p>",
"   <p>",
"    With regard to needlestick injuries involving blood from macaques, blood from healthy animals is extremely unlikely to contain B virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/22\">",
"     22",
"    </a>",
"    ], whereas blood from ill animals has been found on some occasions to contain the virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antiviral medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    , which is converted to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in the GI tract, is considered the drug of choice for postexposure prophylaxis of B virus since it results in higher acyclovir levels than oral acyclovir, and B virus has about a 10-fold higher IC50 for acyclovir than herpes simplex virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7,28,31\">",
"     7,28,31",
"    </a>",
"    ]. Acyclovir is considered the drug of choice for pregnant women due to its experience during pregnancy and is also considered an alternative to valacyclovir for non-pregnant individuals.",
"   </p>",
"   <p>",
"    The dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    is 1 g orally every 8 hours. The dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is 800 mg orally five times per day. Based on the animal data discussed above, postexposure prophylaxis is given for 14 days. Neither acyclovir nor valacyclovir has been approved by the US Food and Drug Administration for prophylaxis of B virus infection.",
"   </p>",
"   <p>",
"    We do not recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    for postexposure prophylaxis of B virus infection given the lack of animal data on its use for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     B VIRUS DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations for treatment of B virus disease are consistent with the B virus Working Group guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]. None of the antiviral agents recommended in the following section has been approved by the US Food and Drug Administration for the treatment of B virus infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with symptoms of B virus disease or with a positive culture for B virus other than a postcleansing culture should be thoroughly evaluated, and treatment should be initiated promptly. In addition to a thorough physical examination, including a full neurologic examination, laboratory testing should include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B virus serology (which should be tested concurrently with serum obtained before or at the time of the exposure if possible)",
"     </li>",
"     <li>",
"      B virus cultures of lesions, conjunctivae, and the oropharynx",
"     </li>",
"     <li>",
"      Pregnancy testing if a woman is of childbearing age",
"     </li>",
"     <li>",
"      Brain MRI (or CT if MRI is not available) &mdash; to assess for brain stem encephalomyelitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/6,12,32\">",
"       6,12,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lumbar puncture with CSF sent for routine chemistry and cell counts, B virus culture, PCR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/33,34\">",
"       33,34",
"      </a>",
"      ], and serology",
"     </li>",
"     <li>",
"      Electroencephalogram should be considered if needed to help to differentiate B virus encephalitis (a brain stem encephalitis that becomes diffuse over time) from herpes simplex encephalitis (usually a unilateral temporal lobe encephalitis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (12.5 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 8 hours) is the drug of choice for treatment of B virus disease in patients without peripheral or central nervous system findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]. This high dose of acyclovir is recommended because of the higher IC",
"    <sub>",
"     50",
"    </sub>",
"    for B virus than for herpes simplex virus. Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours) is the alternative medication. In addition, patients should be switched from acyclovir to ganciclovir if symptoms progress during therapy with acyclovir.",
"   </p>",
"   <p>",
"    IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is considered the drug of choice for treatment of B virus disease in persons with peripheral or central nervous system symptoms or signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]. The rationale for using ganciclovir in patients with nervous system disease is based on its superior efficacy compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in the rabbit model cited above and the successful outcome in a patient with B virus encephalitis treated with ganciclovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Animal studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    High-dose IV antiviral therapy for B virus disease is given for at least two to three weeks and until symptoms resolve, whichever is longer. We recommend that two consecutive oropharyngeal and conjunctival cultures for B virus be obtained after symptoms have resolved and IV therapy is about to be changed to oral therapy as discussed below. In general, cultures for B virus should be obtained and remain negative for 10 to 14 days each time there is a change in therapy or if therapy is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most experts recommend that oral antiviral therapy at postexposure prophylaxis doses be given for up to one year after high-dose IV treatment is discontinued, since B virus might establish latency in humans and intermittent shedding could occur, although this has not been proven. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Antiviral medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Following the completion of antiviral therapy at postexposure prophylaxis doses, many experts suggest lifelong suppression with one of the following regimens, which are based on the regimens for suppression of genital herpes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      500 mg orally once or twice daily",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      400 mg orally twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link&amp;anchor=H44#H44\">",
"     \"Treatment of genital herpes simplex virus infection\", section on 'Treatment recommendations for suppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts feel that antiviral therapy can eventually be discontinued since recurrences of genital herpes simplex virus (a human counterpart to B virus) tend to diminish over time; however, many others feel that antiviral prophylaxis should continue for life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7,25\">",
"     7,25",
"    </a>",
"    ], since there is one report (which is controversial) that B virus may have reactivated months or years after primary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/13\">",
"     13",
"    </a>",
"    ]. Long-term suppressive therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    for up to 10 years, or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    for up to one year, has been well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/35\">",
"     35",
"    </a>",
"    ]. In view of the potential for reactivation of B virus, any decision to stop antiviral prophylaxis should be discussed in detail with the patient, and it is essential to educate the patient regarding signs and symptoms of B virus disease.",
"   </p>",
"   <p>",
"    If antiviral therapy is stopped, sequential oropharyngeal and conjunctival cultures should be performed at least weekly for several weeks to ensure that patients are not shedding virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"     7",
"    </a>",
"    ]. If cultures are negative for at least two weeks after treatment has been discontinued, the frequency of cultures can be reduced and eventually performed once or twice a year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B virus (Cercopithecine herpesvirus 1) causes a herpes simplex virus (HSV)-like infection in macaque monkeys, but can also cause a fatal encephalomyelitis in humans. Fatal cases of B virus infection have been reported after exposures to monkey bites, monkey scratches, cage scratches, a mucosal splash from monkey material, and from infected cell cultures. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Infection of humans'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Macaques become latently infected and virus is shed lifelong in oral and genital secretions and from the conjunctivae, including when animals are asymptomatic. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Natural infection in macaques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately five days to three weeks after an exposure (range two days to five weeks), patients present with one of three patterns of disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vesicular or ulcerative lesions, tingling, pain, or itching at the site of exposure, and local lymphadenopathy.",
"     </li>",
"     <li>",
"      Influenza-like illness with fever and myalgias. Later symptoms may include numbness or paresthesias near the site of exposure, fever, conjunctivitis, abdominal pain, hepatitis, or pneumonitis followed by central nervous system (CNS) symptoms.",
"     </li>",
"     <li>",
"      Nausea and vomiting, and CNS symptoms including headache that may progress to meningismus, cranial nerve deficits, dysarthria, dysphagia, seizures, paralysis, respiratory failure, and coma. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following a potential exposure to B virus, thorough and prompt cleaning of exposed areas should occur, followed by evaluation for the need for postexposure prophylaxis. Cultures and serologies of the exposed individual are often recommended, but remain controversial. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Postexposure evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For individuals who are seen within five days of a high-risk macaque exposure, we recommend post-exposure antiviral prophylaxis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest prophylaxis with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (1 g orally every 8 hours) (",
"      <a class=\"graphic graphic_table graphicRef55170 \" href=\"mobipreview.htm?16/2/16428\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (800 mg five times daily) is an alternative, and we suggest this antiviral agent in pregnant women (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Prophylaxis should be continued for 14 days. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Indications for prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Antiviral medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of B virus disease without peripheral or central nervous system signs or symptoms, we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (12.5 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 8 hours) rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of B virus disease with peripheral or central nervous system signs or symptoms, we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours) rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most clinicians give oral antiviral therapy at postexposure prophylaxis doses for up to one year after high-dose IV treatment is discontinued. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following sequential high-dose IV treatment and oral antiviral therapy at postexposure prophylaxis dosing, many experts use chronic suppression with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      500 mg orally once or twice daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      400 mg orally twice daily. This regimen should be continued indefinitely. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Whitley, RJ, Hilliard, J. Cercopithecine Herpes Virus 1 (B virus). In: Fields Virology, Knipe DM, Howley PM, et al (Eds), Lipincott-Williams &amp; Wilkins, Philadelphia 2007. p.2889-2903.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/2\">",
"      Huff JL, Barry PA. B-virus (Cercopithecine herpesvirus 1) infection in humans and macaques: potential for zoonotic disease. Emerg Infect Dis 2003; 9:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/3\">",
"      Weigler BJ, Hird DW, Hilliard JK, et al. Epidemiology of cercopithecine herpesvirus 1 (B virus) infection and shedding in a large breeding cohort of rhesus macaques. J Infect Dis 1993; 167:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/4\">",
"      Perelygina L, Zhu L, Zurkuhlen H, et al. Complete sequence and comparative analysis of the genome of herpes B virus (Cercopithecine herpesvirus 1) from a rhesus monkey. J Virol 2003; 77:6167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/5\">",
"      Palmer AE. B virus, Herpesvirus simiae: historical perspective. J Med Primatol 1987; 16:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/6\">",
"      Davenport DS, Johnson DR, Holmes GP, et al. Diagnosis and management of human B virus (Herpesvirus simiae) infections in Michigan. Clin Infect Dis 1994; 19:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/7\">",
"      Cohen JI, Davenport DS, Stewart JA, et al. Recommendations for prevention of and therapy for exposure to B virus (cercopithecine herpesvirus 1). Clin Infect Dis 2002; 35:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Fatal Cercopithecine herpesvirus 1 (B virus) infection following a mucocutaneous exposure and interim recommendations for worker protection. MMWR Morb Mortal Wkly Rep 1998; 47:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/9\">",
"      Holmes GP, Hilliard JK, Klontz KC, et al. B virus (Herpesvirus simiae) infection in humans: epidemiologic investigation of a cluster. Ann Intern Med 1990; 112:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/10\">",
"      HUMMELER K, DAVIDSON WL, HENLE W, et al. Encephalomyelitis due to infection with Herpesvirus simiae (herpes B virus); a report of two fatal, laboratory-acquired cases. N Engl J Med 1959; 261:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/11\">",
"      Sabin, AB. Fatal B virus encephalomyelitis in a physician working with monkeys. J Clin Invest 1949; 28:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/12\">",
"      DAVIDSON WL, HUMMELER K. B virus infection in man. Ann N Y Acad Sci 1960; 85:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/13\">",
"      Fierer J, Bazely P, Braude AI. Herpes B virus encephalomyelitis presenting as ophthalmic zoster. A possible latent infection reactivated. Ann Intern Med 1973; 79:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/14\">",
"      Engel GA, Jones-Engel L, Schillaci MA, et al. Human exposure to herpesvirus B-seropositive macaques, Bali, Indonesia. Emerg Infect Dis 2002; 8:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/15\">",
"      Ritz N, Curtis N, Buttery J, Babl FE. Monkey bites in travelers: should we think of herpes B virus? Pediatr Emerg Care 2009; 25:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/16\">",
"      Jones-Engel L, Engel GA, Heidrich J, et al. Temple monkeys and health implications of commensalism, Kathmandu, Nepal. Emerg Infect Dis 2006; 12:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/17\">",
"      Schillaci MA, Jones-Engel L, Engel GA, et al. Prevalence of enzootic simian viruses among urban performance monkeys in Indonesia. Trop Med Int Health 2005; 10:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/18\">",
"      Jensen K, Alvarado-Ramy F, Gonz&aacute;lez-Mart&iacute;nez J, et al. B-virus and free-ranging macaques, Puerto Rico. Emerg Infect Dis 2004; 10:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/19\">",
"      Ostrowski SR, Leslie MJ, Parrott T, et al. B-virus from pet macaque monkeys: an emerging threat in the United States? Emerg Infect Dis 1998; 4:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/20\">",
"      Weigler BJ, Roberts JA, Hird DW, et al. A cross sectional survey for B virus antibody in a colony of group housed rhesus macaques. Lab Anim Sci 1990; 40:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/21\">",
"      KEEBLE SA, CHRISTOFINIS GJ, WOOD W. Natural virus-B infection in rhesus monkeys. J Pathol Bacteriol 1958; 76:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/22\">",
"      KEEBLE SA. B virus infection in monkeys. Ann N Y Acad Sci 1960; 85:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/23\">",
"      Vizoso AD. Recovery of herpes simiae (B virus) from both primary and latent infections in rhesus monkeys. Br J Exp Pathol 1975; 56:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/24\">",
"      Zwartouw HT, Boulter EA. Excretion of B virus in monkeys and evidence of genital infection. Lab Anim 1984; 18:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/25\">",
"      Holmes GP, Chapman LE, Stewart JA, et al. Guidelines for the prevention and treatment of B-virus infections in exposed persons. The B virus Working Group. Clin Infect Dis 1995; 20:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/26\">",
"      Freifeld AG, Hilliard J, Southers J, et al. A controlled seroprevalence survey of primate handlers for evidence of asymptomatic herpes B virus infection. J Infect Dis 1995; 171:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/27\">",
"      Goldstein EJ, Pryor EP 3rd, Citron DM. Simian bites and bacterial infection. Clin Infect Dis 1995; 20:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/28\">",
"      Boulter EA, Thornton B, Bauer DJ, Bye A. Successful treatment of experimental B virus (Herpesvirus simiae) infection with acyclovir. Br Med J 1980; 280:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/29\">",
"      Zwartouw HT, Humphreys CR, Collins P. Oral chemotherapy of fatal B virus (herpesvirus simiae) infection. Antiviral Res 1989; 11:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/30\">",
"      Simon MA, Daniel MD, Lee-Parritz D, et al. Disseminated B virus infection in a cynomolgus monkey. Lab Anim Sci 1993; 43:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/31\">",
"      Focher F, Lossani A, Verri A, et al. Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. Antimicrob Agents Chemother 2007; 51:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/32\">",
"      BREEN GE, LAMB SG, OTAKI AT. Monkey-bite encephalomyelitis; report of a case; with recovery. Br Med J 1958; 2:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/33\">",
"      Scinicariello F, English WJ, Hilliard J. Identification by PCR of meningitis caused by herpes B virus. Lancet 1993; 341:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/34\">",
"      Perelygina L, Patrusheva I, Manes N, et al. Quantitative real-time PCR for detection of monkey B virus (Cercopithecine herpesvirus 1) in clinical samples. J Virol Methods 2003; 109:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32583/abstract/35\">",
"      Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 2002; 186 Suppl 1:S40.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8282 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32583=[""].join("\n");
var outline_f31_52_32583=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Natural infection in macaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infection of humans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POSTEXPOSURE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Postexposure cultures and serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cultures and serology in nonhuman primates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diagnostic laboratories",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      POSTEXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Indications for prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antiviral medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      B VIRUS DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8282\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8282|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/2/16428\" title=\"table 1\">",
"      B virus postexposure ppx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31401?source=related_link\">",
"      Zoonoses from cats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/24/29065?source=related_link\">",
"      Zoonoses from dogs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26986?source=related_link\">",
"      Zoonoses from pets other than dogs and cats",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_52_32584="Initial chemotherapy for patients with high risk multiple myeloma";
var content_f31_52_32584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial chemotherapy for patients with high risk multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32584/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32584/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32584/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32584/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32584/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32584/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/52/32584/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. Potential complications include anemia, hypercalcemia, renal insufficiency, infection, and skeletal lesions.",
"   </p>",
"   <p>",
"    When multiple myeloma is suspected, the diagnosis must be carefully verified. For example, patients who have 10 percent or more clonal plasma cells in the marrow but no evidence of end organ damage that can be attributed to the plasma cell disorder (smoldering multiple myeloma) do not require therapy because there is no proof of clear benefit with currently available therapies and some of these patients remain stable without treatment over extended periods of time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H2#H2\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Verification of the diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of multiple myeloma requires the presence of end organ damage (hypercalcemia, renal failure, anemia, or bone disease) that is felt related to the plasma cell proliferative disorder. Once the diagnosis of multiple myeloma is confirmed, the next step includes testing for those abnormalities that help predict outcome following treatment. Individual cases are stratified into either high risk or standard risk multiple myeloma based upon the results of one or preferably both of the following tests (",
"    <a class=\"graphic graphic_table graphicRef78344 \" href=\"mobipreview.htm?24/32/25099\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      FISH for detection of t(11;14), t(4;14), t(6;14), t(14;16), t(14;20), del17p13, and trisomies of odd numbered chromosomes",
"     </li>",
"     <li>",
"      Conventional cytogenetics (karyotyping) for detection of del 13, monosomy 13, or hypodiploidy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This risk stratification scheme is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=see_link&amp;anchor=H8#H8\">",
"     \"Staging and prognostic studies in multiple myeloma\", section on 'Cytogenetic abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 15 percent of patients with symptomatic multiple myeloma are categorized as having high risk disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/1\">",
"     1",
"    </a>",
"    ]. This includes patients with t(14;16), t(14;20), or del17p13 by FISH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/2\">",
"     2",
"    </a>",
"    ]. These patients have a median survival of approximately two to three years despite standard treatment. Patients with a high risk signature on gene expression profiling are also considered to have high risk MM, but this test is not recommended on a routine basis. The presence of trisomies in patients with high risk cytogenetics may ameliorate some of the adverse prognostic effects of high risk cytogenetic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with high risk multiple myeloma should be considered for novel therapeutic strategies, since they do poorly with all conventional treatment options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/4-11\">",
"     4-11",
"    </a>",
"    ]. Novel strategies (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -based initial therapy) may partially overcome some of these high risk characteristics.",
"   </p>",
"   <p>",
"    The treatment of patients with high risk multiple myeloma will be discussed here. The treatment of standard risk multiple myeloma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28698?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous hematopoietic cell transplantation (HCT) is a major component of the treatment of symptomatic patients with standard or high risk multiple myeloma. Given the importance of HCT, the initial therapy of patients with symptomatic multiple myeloma varies depending on whether patients are eligible or not to pursue autologous HCT. For patients who are candidates for HCT, chemotherapy given prior to stem cell collection should avoid agents that may impair harvest. In contrast, the impact of chemotherapy agents on stem cell collection does not affect the choice of agents given to patients who are not candidates for HCT. Guidelines for HCT eligibility criteria are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H7#H7\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Determining transplant eligibility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with high risk multiple myeloma have been included in the trials and studies that have helped to define HCT as an important option for patients with standard risk disease. In addition, they have been included in trials of novel agents and more intensive therapy.",
"   </p>",
"   <p>",
"    The goal of therapy in patients with high risk myeloma is to achieve and sustain a complete response. Unfortunately, patients with high risk myeloma have an adverse outcome compared with standard risk patients, even when HCT is employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/12\">",
"     12",
"    </a>",
"    ]. The majority of patients with high risk multiple myeloma have an initial partial response to traditional chemotherapy followed by HCT or traditional chemotherapy alone. However, as shown in retrospective studies, high risk patients relapse rapidly with a median progression-free survival of only 8 to 14 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/6-8,11,13-15\">",
"     6-8,11,13-15",
"    </a>",
"    ]. This compares to an approximately 25-month median progression-free survival among all patients with multiple myeloma treated with HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the benefit of HCT may be less in high risk patients compared with standard risk patients. The value of HCT in high risk patients may be augmented by using post&ndash;HCT maintenance therapy to delay time to relapse. Alternatively, HCT can be used as a second-line option at the time of relapse. As described below, as in standard and intermediate risk patients, we routinely collect stem cells from high risk patients who appear to be candidates for HCT after a few cycles of induction chemotherapy. The choice of initial therapy differs to some extent in high risk disease between those who are candidates for HCT and those who are not. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Our treatment approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor outcomes with available strategies have lead to the investigation of novel treatments in high risk disease. There is a paucity of data to guide one in the selection of novel therapeutic strategies. Options that have been investigated include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of new agents, especially",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based regimens, early in the disease course [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consideration of routine maintenance following initial therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consideration of allogeneic HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. However, there is some concern about allogeneic HCT approaches in myeloma, as described below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with high risk multiple myeloma should also strongly consider enrollment in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bortezomib-based initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preclinical data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    may act through targeting NFKappaB, which appears to be activated more frequently in high risk disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/23\">",
"     23",
"    </a>",
"    ]. Retrospective analyses and early reports from prospective trials of bortezomib suggest that this agent may abrogate some high risk prognostic markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/24-31\">",
"     24-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase III randomized trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (VMP) compared with MP in 682 patients with newly diagnosed multiple myeloma has reported that high risk myeloma patients (N=26) treated with VMP had the same time to progression and overall survival rates as standard risk patients on subset analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/32\">",
"       32",
"      </a>",
"      ]. Bortezomib appeared to eliminate t(4;14), t(14;16) and del(17p) as prognostic factors.",
"     </li>",
"     <li>",
"      In another phase III trial, 354 patients with previously untreated myeloma were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (PAD) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , doxorubicin, dexamethasone (VAD), both followed by high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      and maintenance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/33\">",
"       33",
"      </a>",
"      ]. A subgroup analysis of the 37 patients with del(17p) after a median follow-up of 41 months demonstrated significantly longer median progression-free survival (26 versus 12 months) and three-year overall survival (69 versus 17 percent) among those assigned to PAD. No significant difference in outcome was seen among patients with other chromosomal abnormalities.",
"     </li>",
"     <li>",
"      A comparison of the total therapy 2 (TT2) trial that did not incorporate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      and the total therapy 3 (TT3) trial that did also suggests a role for bortezomib in high risk disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/26,29,30\">",
"       26,29,30",
"      </a>",
"      ]. In TT2, the subset of patients with t(4;14) had a significantly shorter event-free and overall survival when compared with patients who lack this translocation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/31\">",
"       31",
"      </a>",
"      ]. This difference in event-free and overall survival disappeared in patients treated with TT3.",
"     </li>",
"     <li>",
"      A case series of 507 patients with newly diagnosed multiple myeloma treated with four cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (VD) prior to autologous HCT reported that t(4;14) and del(17p) remain predictors of poor outcome with this regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/34\">",
"       34",
"      </a>",
"      ]. However, when compared with the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and dexamethasone (VAD), VD resulted in superior event-free and overall survival rates for patients with t(4;14), but did not appear to improve outcomes for those with del(17p). As a result of this and other studies, t(4;14), previously thought to be high risk myeloma, is now considered intermediate risk, while del(17p) remains a marker of high risk disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all patients who are candidates for HCT,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    -containing regimens should be avoided prior to the collection of stem cells, since their use has been associated with damage to the hematopoietic stem cell compartment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transplant or maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with high risk multiple myeloma who are candidates for HCT, we suggest the administration of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -based regimen early in the disease course and targeting complete response as a goal of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/35\">",
"     35",
"    </a>",
"    ]. Although available data are limited, we administer a bortezomib-based maintenance therapy in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/36\">",
"     36",
"    </a>",
"    ]. Allogeneic HCT or maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    do not appear to show a survival benefit in high risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report combined the results of two prospective trials that investigated the use of autologous HCT followed by nonmyeloablative allogeneic HCT for high risk patients with an HLA-identical sibling (46 patients) or a second autologous HCT for high risk patients without an HLA-identical sibling (166 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/37\">",
"       37",
"      </a>",
"      ]. At a median follow-up of 24 months, patients treated with tandem autologous HCT had similar event-free survival (35 versus 32 percent) and overall survival (47 versus 35 percent) when compared with those who underwent autologous HCT followed by nonmyeloablative allogeneic HCT. This lack of a difference in event-free or overall survival rates persisted at a median follow-up of 56 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective randomized trial of 597 myeloma patients younger than 65 years who had undergone tandem autologous HCT reported significantly improved event-free, relapse-free, and overall survival rates with the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      maintenance therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/38\">",
"       38",
"      </a>",
"      ]. However, on subgroup analysis it was without benefit in patients who had a deletion of chromosome 13.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two trials that did not stratify patients according to risk status have reported an improvement in progression-free survival when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    is administered as maintenance therapy following hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In both the trials an increased number of second cancers occurred in the lenalidomide treated arm. Therefore, if clinical circumstances dictate the need for post-transplant lenalidomide for high risk myeloma, then the risk of second cancers must be considered and discussed with the patient.",
"   </p>",
"   <p>",
"    Detailed discussions of allogeneic HCT in multiple myeloma and the use of maintenance therapy after HCT are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/28/36296?source=see_link\">",
"     \"Allogeneic hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link&amp;anchor=H13#H13\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Maintenance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with high risk multiple myeloma who are not candidates for HCT, we suggest the administration of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -based regimen as initial therapy (eg, bortezomib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ). We prefer this approach because there is evidence from nonrandomized trials and preliminary data from randomized trials of regimens containing bortezomib that patients have superior survival responses to this agent irrespective of high risk chromosomal changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OUR TREATMENT APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patients who are candidates for HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have the following specific approach to the treatment of patients with high risk multiple myeloma who are candidates for HCT (",
"    <a class=\"graphic graphic_algorithm graphicRef73792 \" href=\"mobipreview.htm?11/52/12111\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/35\">",
"     35",
"    </a>",
"    ]. We initiate therapy with four to six cycles of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    containing regimen, preferably bortezomib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (VRD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/2,43,44\">",
"     2,43,44",
"    </a>",
"    ]. We then collect stem cells and cryopreserve them. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The VRD regimen can be administered as follows:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once weekly (days 1, 8, 15) in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      25 mg days 1 to 14 and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      20 mg on day of and day after bortezomib (or 40 mg days 1, 8, 15). Bortezomib can be administered intravenously or subcutaneously (SC) and, in general, SC is preferred due to a lower risk of neuropathy. Cycles are administered every three weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After collection of stem cells, we recommend proceeding to transplantation if the patient is not in complete remission. All patients are given long-term maintenance with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -based regimen, such as bortezomib intravenously every two weeks or bortezomib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/45\">",
"     45",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . In patients who did not receive initial transplantation, we perform autologous HCT at first disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patients who are not candidates for HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with high risk multiple myeloma who are not candidates for HCT, we use a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    containing regimen, preferably bortezomib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (VRD) (",
"    <a class=\"graphic graphic_algorithm graphicRef79012 \" href=\"mobipreview.htm?24/59/25534\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/2,44\">",
"     2,44",
"    </a>",
"    ]. Other options include bortezomib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (VMP) and bortezomib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , dexamethasone (VCD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/17,46\">",
"     17,46",
"    </a>",
"    ]. With each of these regimens, we administer bortezomib once weekly rather than twice weekly because this approach has demonstrated lower rates of peripheral neuropathy without compromising efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/47\">",
"     47",
"    </a>",
"    ]. Bortezomib can be administered intravenously or subcutaneously (SC) and, in general, SC is preferred due to a lower risk of neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The VRD regimen can be administered as follows:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once weekly (days 1, 8, 15) in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      25 mg days 1 to 14 and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      20 mg on day of and day after bortezomib (or 40 mg days 1, 8, 15). Cycles are administered every three weeks.",
"     </li>",
"     <li>",
"      The VMP regimen can be administered as follows (",
"      <a class=\"graphic graphic_table graphicRef55107 \" href=\"mobipreview.htm?27/39/28286\">",
"       table 2",
"      </a>",
"      ):",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once weekly (days 1, 8, 15 and 22) for six to nine five-week cycles in combination with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      9",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once daily on days 1 through 4 of each cycle.",
"     </li>",
"     <li>",
"      The VCD regimen can be administered as follows (",
"      <a class=\"graphic graphic_table graphicRef50061 \" href=\"mobipreview.htm?32/43/33470\">",
"       table 3",
"      </a>",
"      ):",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      1.5",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once weekly (days 1, 8, 15 and 22) for four five-week cycles in combination with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once weekly (days 1, 8, 15, and 22) and oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      40 mg once weekly (days 1, 8, 15, and 22).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"      -based regimens such as VRD, VMP, and VCD are administered with antiviral prophylaxis such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      400 mg twice daily throughout treatment. Some clinicians also administer prophylaxis with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      on Monday, Wednesday, and Friday of each week for prevention of Pneumocystis infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If an urgent response is needed, an initial six-week cycle of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    1.3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice weekly (days 1, 4, 8, 11, 22, 25, 29 and 32) can be administered along with the same doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in the VMP regimen described above before starting the once weekly schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/24\">",
"     24",
"    </a>",
"    ]. Candidates for this more aggressive approach include patients with acute renal failure from light chain cast nephropathy or patients with an aggressive disease presentation.",
"   </p>",
"   <p>",
"    For patients with moderate or severe impairment of hepatic function (serum bilirubin &ge;1.5 times the upper limit of normal), we initiate therapy with a reduced dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    (0.7",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MONITORING RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be evaluated before each treatment cycle to determine how their disease is responding to therapy. The preferred method is the measurement of monoclonal (M) protein in serum or urine. Free light chain (FLC) measurements are reserved for patients with unmeasurable protein in the serum and urine.",
"   </p>",
"   <p>",
"    Among patients without an M protein in serum or urine and normal FLC ratio, further evaluation includes bone marrow immunohistochemistry or immunofluorescence and plasma cell labeling index. Details on how to determine response to therapy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31526?source=see_link\">",
"     \"Evaluating response to treatment of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Goal of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with multiple myeloma demonstrate an overall survival benefit from obtaining either a complete response or a very good partial response to therapy; overall survival benefits are seen even for patients who do not obtain a complete response (CR) to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32584/abstract/49\">",
"     49",
"    </a>",
"    ]. However, among patients with high risk multiple myeloma, patients who achieve a complete response have a longer overall survival than those who do not. This was demonstrated in a landmark survival analysis of 44 patients with high risk myeloma defined by gene expression profiling. This study demonstrated significantly higher rates of 24-month overall survival for those achieving a complete response compared with those who failed to achieve a complete response (approximately 80 versus 30 percent, respectively). Thus complete response is a goal of therapy in high risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RELAPSED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for relapsed high risk multiple myeloma include an autologous HCT, allogeneic HCT as part of a clinical trial, or treatment with salvage chemotherapy. Few such patients are candidates for allogeneic HCT due to co-morbidities and age restrictions. These options are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link\">",
"     \"Treatment of relapsed or refractory multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/28/36296?source=see_link\">",
"     \"Allogeneic hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial evaluation of the patient diagnosed with multiple myeloma includes testing for those abnormalities that help predict the response to treatment. Individual cases are stratified into either high risk or standard risk multiple myeloma based upon the results of FISH for specific translocations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deletions, conventional cytogenetics, and the plasma cell labeling index. This risk stratification scheme is presented in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with high risk myeloma have a worse outcome than standard risk patients after treatment with standard induction followed by HCT therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Poor outcomes with available strategies have lead to the investigation of novel treatments in high risk disease. The best option for these patients would be to enroll in a clinical trial designed to test one of these hypotheses. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are not candidates for clinical trials or those who choose not to enroll in a clinical trial, novel approaches to the treatment of high risk disease have included the administration of novel agents early in the disease course, the use of routine maintenance therapy, and the use of allogeneic approaches such as an autologous HCT followed by a non-myeloablative allogeneic HCT. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with high risk multiple myeloma who are candidates for HCT, we suggest the administration of a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based induction regimen targeting complete response as a treatment goal (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Following the completion of HCT, we administer a bortezomib-based maintenance therapy. For patients with high risk multiple myeloma who are not candidates for HCT, we suggest the administration of a bortezomib-based regimen as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We prefer this approach because there is evidence from nonrandomized trials and preliminary data from randomized trials of regimens containing bortezomib that patients have superior survival responses to this agent irrespective of high risk chromosomal changes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment options'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Our treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be evaluated before each treatment cycle to determine how their disease is responding to therapy. Details on how to determine response to therapy are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31526?source=see_link\">",
"       \"Evaluating response to treatment of multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment options for relapsed high risk multiple myeloma include an autologous HCT, allogeneic HCT as part of a clinical trial, or treatment with salvage chemotherapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Relapsed disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/1\">",
"      Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007; 21:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/2\">",
"      Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/3\">",
"      Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/4\">",
"      Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My&eacute;lome. Blood 2007; 109:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/5\">",
"      Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005; 80:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/6\">",
"      Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23:7069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/7\">",
"      Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/8\">",
"      Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106:2837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/9\">",
"      Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998; 16:3832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/10\">",
"      Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/11\">",
"      Chang H, Qi XY, Samiee S, et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 2005; 36:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/12\">",
"      Pineda-Roman M, Barlogie B, Anaissie E, et al. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer 2008; 112:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/13\">",
"      Tricot G, Spencer T, Sawyer J, et al. Predicting long-term (&gt; or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002; 116:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/14\">",
"      Jacobson J, Barlogie B, Shaughnessy J, et al. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol 2003; 122:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/15\">",
"      Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009; 114:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/16\">",
"      Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/17\">",
"      Fonseca R. Strategies for risk-adapted therapy in myeloma. Hematology Am Soc Hematol Educ Program 2007; :304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/18\">",
"      Shustik C, Belch A, Robinson S, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 2007; 136:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/19\">",
"      Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99:3163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/20\">",
"      Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/21\">",
"      Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/22\">",
"      Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/23\">",
"      Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/24\">",
"      Mateos MV, Hern&aacute;ndez JM, Hern&aacute;ndez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/25\">",
"      Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/26\">",
"      Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/27\">",
"      Chang H, Trieu Y, Qi X, et al. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007; 31:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/28\">",
"      Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007; 21:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/29\">",
"      van Rhee F, Szymonifka J, Anaissie E, et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010; 116:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/30\">",
"      Shaughnessy JD, Zhou Y, Haessler J, et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol 2009; 147:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/31\">",
"      Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008; 140:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/32\">",
"      San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/33\">",
"      Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012; 119:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/34\">",
"      Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28:4630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/35\">",
"      Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009; 84:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/36\">",
"      Benevolo G, Larocca A, Gentile M, et al. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. Cancer 2011; 117:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/37\">",
"      Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107:3474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/38\">",
"      Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108:3289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/39\">",
"      Schilling G, Hansen T, Shimoni A, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008; 22:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/40\">",
"      Moreau P, Garban F, Attal M, et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008; 112:3914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/41\">",
"      Attal M, Cristini C, Marit G, et al. Lenalidomide maintenance after transplantation for myeloma. (abstract 8018). J Clin Oncol 2010; 28:577s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/42\">",
"      McCarthy PL, Owzar K, Anderson KC, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma: CALBG 100104 (abstract 8017). J Clin Oncol 2010; 28:577s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/43\">",
"      Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/44\">",
"      Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/45\">",
"      Sonneveld P, Schmidt-Wolf I, van der Hold, et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing Botezomib, Doxorubicin, Dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (abstract 40). Blood 2010; 116:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/46\">",
"      Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009; 23:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/47\">",
"      Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116:4745.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198424.htm (Accessed on February 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32584/abstract/49\">",
"      Haessler J, Shaughnessy JD Jr, Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13:7073.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6644 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32584=[""].join("\n");
var outline_f31_52_32584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bortezomib-based initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transplant or maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OUR TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patients who are candidates for HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patients who are not candidates for HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MONITORING RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Goal of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RELAPSED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6644\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6644|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/52/12111\" title=\"algorithm 1\">",
"      Therapy approach MM I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?24/59/25534\" title=\"algorithm 2\">",
"      Therapy approach MM II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6644|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/32/25099\" title=\"table 1\">",
"      Risk stratification of myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/39/28286\" title=\"table 2\">",
"      VMP for multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/43/33470\" title=\"table 3\">",
"      VCd CyBorD for multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/28/36296?source=related_link\">",
"      Allogeneic hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31526?source=related_link\">",
"      Evaluating response to treatment of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28698?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=related_link\">",
"      Staging and prognostic studies in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_52_32585="EPS tracing AVRT initiation termination";
var content_f31_52_32585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Initiation and termination of an atrioventricular reentrant tachycardia captured during invasive electrophysiology studies (EPS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 708px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During atrial pacing (S1) a premature atrial beat (S2) is blocked antegradely in the accessory pathway and conducts through the atrioventricular node with along delay (A2H2 interval), which allows for the recovery of the accessory pathway before retrograde conduction (panel A). The mechanism is an orthodromic atrioventricular reentrant tachycardia (AVRT) using a left-sided pathway, suggested by the atrial activation sequence; earliest retrograde atrial activation during the first echo beat of AVRT (Ae) is in the mid coronary sinus (CSm). A single venticular premature beat (VPB) terminates the AVRT (panel B). The VPB conducts to the left atrium, but encounters the refractory period of the AV node and is blocked, interrupting conduction in the antegrade limb and terminating the arrhythmia.",
"    <div class=\"footnotes\">",
"     V: ventricular electrogram; A: atrial electrogram; NSR: normal sinus rhythm; d: distal; p: proximal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32585=[""].join("\n");
var outline_f31_52_32585=null;
var title_f31_52_32586="Diagnosis, treatment, and prevention of drug-resistant tuberculosis";
var content_f31_52_32586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32586/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32586/contributors\">",
"     Neil W Schluger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32586/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32586/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/52/32586/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/52/32586/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/52/32586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide. Its management has become more complex because of increased resistance to commonly-used anti-TB drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7497?source=see_link\">",
"     \"Epidemiology and molecular mechanisms of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of drug-resistant TB can be difficult, and may necessitate the use of second-line drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resectional surgery. Therefore, management of such patients should be undertaken by individuals with expertise in this area, or in very close consultation with such individuals. Good patient outcomes depend upon rapid and accurate diagnosis together with administration of proper therapy with close monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis, treatment, and prevention of drug-resistant M. tuberculosis will be reviewed here. The treatment of drug-susceptible TB is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitions to describe the different types of drug-resistant tuberculosis (TB) include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term &ldquo;drug-resistant TB&rdquo; refers to cases of TB caused by an isolate of M. tuberculosis that is resistant to one of the first-line anti-TB drugs:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The term &ldquo;multidrug-resistant TB&rdquo; (MDR-TB) refers to an isolate of M. tuberculosis that is resistant to at least",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , and possibly additional agents.",
"     </li>",
"     <li>",
"      The term &ldquo;extensively drug-resistant TB&rdquo; (XDR-TB) refers to an isolate of M. tuberculosis that is resistant to at least",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , and fluoroquinolones, as well as either aminoglycosides (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"       kanamycin",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/59/11189?source=see_link\">",
"       capreomycin",
"      </a>",
"      , or both [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34743?source=see_link&amp;anchor=H2#H2\">",
"       \"Epidemiology of extensively drug-resistant tuberculosis\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The term &ldquo;totally drug-resistant TB&rdquo; (TDR-TB) refers to an isolate of M. tuberculosis resistant to all locally tested medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. However the published studies initially describing TDR-TB did not including susceptibility testing for less frequently used agents with activity against TB, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"       cycloserine",
"      </a>",
"      , terizidone, clofazimine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      , or carbapenems. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34743?source=see_link&amp;anchor=H2#H2\">",
"       \"Epidemiology of extensively drug-resistant tuberculosis\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary drug resistance is said to occur in a patient who has never received anti-TB therapy.",
"     </li>",
"     <li>",
"      Secondary drug resistance refers to the development of resistance during or following chemotherapy in patients who had previously had drug-susceptible TB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations and radiographic features of drug-resistant tuberculosis (TB) are comparable to those of drug-susceptible disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A careful history must be obtained prior to initiation of treatment, for clues that drug resistance may be an issue of concern. Sputum should be collected for baseline culture and sensitivity data prior to initiation of treatment. Rapid testing is an increasingly utilized tool for prompt detection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Demographic and historical features that should raise the suspicion of drug-resistant TB include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Previous treatment for active TB, particularly if therapy was self-administered.",
"     </li>",
"     <li>",
"      TB treatment failure with an intermittently dosed regimen in the setting of advanced HIV infection.",
"     </li>",
"     <li>",
"      Acquisition of TB in a region with known high rates of drug resistance.",
"     </li>",
"     <li>",
"      Contact with a patient with drug-resistant TB.",
"     </li>",
"     <li>",
"      Failure to respond to empiric therapy, particularly if adherence has been documented.",
"     </li>",
"     <li>",
"      Receipt of fluoroquinolone therapy for treatment of symptoms consistent with community-acquired pneumonia later proven to be TB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complete records of all previous cultures, drug susceptibility testing results, and treatment regimens must be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Culture and sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of drug-resistant TB depends upon culture and sensitivity testing of sputum or other specimens prior to initiation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/8\">",
"     8",
"    </a>",
"    ]. Drug susceptibility testing (DST) for first and second-line agents should be performed at a reliable reference laboratory. This is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=see_link&amp;anchor=H23#H23\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\", section on 'Drug susceptibility testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Every attempt should be made to collect sputum for culture prior to initiation of treatment. If a patient cannot produce an expectorated sputum, induction should be performed. If induction is not successful, bronchoscopy may be useful for obtaining diagnostic material for culture; the risks of nosocomial transmission of potentially drug-resistant TB must be weighed against the benefits of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/9\">",
"     9",
"    </a>",
"    ]. For patients with exclusively extrapulmonary disease, samples of involved tissue (eg, lymph nodes, bone, blood) should be obtained for culture and sensitivity testing as well as histopathology.",
"   </p>",
"   <p>",
"    Failure to convert from a positive to negative sputum AFB smear during treatment may be an indicator for drug resistance in some cases. In one study of 93 adults initiating treatment for TB in Peru, persistent smear positivity at 60 days had a positive predictive value for detecting multidrug resistance of 67 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/10\">",
"     10",
"    </a>",
"    ]. However, drug susceptibility testing should not be limited to those with persistent smear positivity after a trial of first-line therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rapid testing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15478205\">",
"    <span class=\"h3\">",
"     Nucleic acid tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid testing using molecular techniques can speed the diagnosis and control of MDR-TB infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The assay GeneXpert",
"      <span class=\"nowrap\">",
"       MTB/RIF",
"      </span>",
"      is an automated nucleic acid amplification test for M. tuberculosis and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      resistance (rpoB gene). In a study including 1730 patients with suspected TB, the test correctly identified 98 percent of patients with smear positive TB and 72 percent of patients with smear",
"      <span class=\"nowrap\">",
"       negative/culture",
"      </span>",
"      positive TB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/11\">",
"       11",
"      </a>",
"      ]. The accuracy for identification of rifampin resistance was 98 percent. The assay is simple to perform with minimal training, is not prone to cross-contamination, and requires minimal biosafety facilities. Results are available in two hours. False positive results can occur in regions with low rates of drug resistance, thus standard DST should still be performed.",
"     </li>",
"     <li>",
"      The assay MTBDRplus is a molecular probe capable of detecting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      resistance mutations (rpoB gene for rifampin resistance; katG and inhA genes for isoniazid resistance). In an evaluation of 536 smear positive specimens from patients at risk for MDR-TB in South Africa, the molecular probe was &ge;99 percent sensitive and specific for multidrug TB resistance compared with standard DST; results were available in one to two days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/12\">",
"       12",
"      </a>",
"      ]. Since the assay does not depend on culture, it yielded results even in specimens that were contaminated or had no growth. Molecular testing was successful even when the AFB smear was negative. Use of the assay can reduce time to initiation of therapy for MDR-TB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Direct DNA sequencing analysis of sputum specimens is also a useful method for detection of drug-resistant TB, and results may be available in four days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These assays hold promise for the early and rapid detection of drug resistance. Limitations include cost, identification of only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    resistance, and inability to identify which patients are &ldquo;sputum smear positive&rdquo; for infection control and treatment monitoring purposes.",
"   </p>",
"   <p>",
"    The WHO 2011 guidelines for treatment of MDR-TB favor rapid drug susceptibility testing for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and rifampicin (or for rifampicin alone) over conventional testing or no testing at the time of diagnosis of TB, subject to available resources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15478213\">",
"    <span class=\"h3\">",
"     Culture based tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic observation drug susceptibility (MODS) and thin layer agar (TLA) are tests in which drug-free and drug-containing media (liquid for MODS, solid for TLA) are inoculated with patient specimens and cultures are microscopically examined for early growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/16\">",
"     16",
"    </a>",
"    ]. Growth of M. tuberculosis in or on a drug-free media indicates a positive culture, whereas growth in or on both drug-free and drug-containing media indicates resistance. MODS is faster than automated liquid culture (results can be available in as little as seven days) and can be used in smear-positive and smear-negative cases. The World Health Organization (WHO) has recommended that MODS be used as an interim diagnostic tool while the capacity for other tools, including drug susceptibility and automated liquid culture, are developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT OF MONORESISTANT TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical approach to treatment of monoresistant disease varies depending on the agent to which the isolate is resistant. The trials discussed below were all performed in HIV-negative patients. In HIV-infected patients, many experts choose to prolong therapy for three additional months. Dosing is summarized in the Tables (",
"    <a class=\"graphic graphic_table graphicRef55978 \" href=\"mobipreview.htm?25/12/25804\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66493 \" href=\"mobipreview.htm?13/8/13453\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Isoniazid monoresistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (INH) monoresistant tuberculosis (TB) has not been evaluated rigorously in randomized trials; as a result, treatment approaches are generally based on expert opinion informed by retrospective or single arm studies.",
"   </p>",
"   <p>",
"    In general, most patients with INH monoresistance should be treated with a rifamycin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef55978 \" href=\"mobipreview.htm?25/12/25804\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/17\">",
"     17",
"    </a>",
"    ]. The duration of therapy should be six to nine months (or four months after culture conversion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], which is based on trials conducted by the Hong Kong Chest",
"    <span class=\"nowrap\">",
"     Service/British",
"    </span>",
"    Medical Research Council; these demonstrated success rates of 95 to 98 percent among 107 patients with INH-resistant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/20\">",
"     20",
"    </a>",
"    ]. The above treatment approach is also supported by a retrospective study of patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    monoresistant TB treated for six months; rates of treatment failure or relapse were comparable to patients with drug-susceptible TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/19\">",
"     19",
"    </a>",
"    ], although for many patients the duration of therapy was extended because pyrazinamide was not administered for the entire six months initially. It is reasonable to prolong therapy for an additional three months in HIV-infected patients.",
"   </p>",
"   <p>",
"    In the setting of \"low-level\" INH resistance, (resistant to a concentration of 0.2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    but sensitive to 2.0",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    some experts favor continuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    . In vitro",
"    <em>",
"    </em>",
"    studies provide some support for this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/21\">",
"     21",
"    </a>",
"    ], although, in general, favorable outcomes for patients with INH-monoresistant TB appear to be driven primarily by continuing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    throughout the course of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some favor the addition of a fluoroquinolone for treatment of INH monoresistant TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In one study of 328 patients with smear-positive TB randomized to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ), culture negativity after eight weeks was comparable between the groups (55 and 60 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/24\">",
"     24",
"    </a>",
"    ]. A retrospective Danish study suggested that inclusion of a fluoroquinolone in the treatment regimen was associated with a slightly higher treatment success rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8895813\">",
"     'Fluoroquinolones'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For treatment of patients for whom drug susceptibility testing is not available but are known to reside in a region with a background level of INH resistance &gt;7 percent, an acceptable approach consists of a standard initial phase (eg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ), followed by continuation phase consisting of isoniazid and rifampin with addition of ethambutol (rather than isoniazid and rifampin alone). This is the recommendation of the World Health Organization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\", section on 'Initial phase'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\", section on 'Continuation phase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Effective therapy for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    monoresistant TB is associated with very high bacteriologic and clinical response rates (&gt;95 percent), and low relapse rates (&lt;5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rifampin monoresistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    monoresistance is less common than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    monoresistance and has been observed most frequently in HIV-positive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Rifampin monoresistance may be more likely to develop in HIV-infected patients with advanced immunosuppression (eg, CD4 cell counts",
"    <span class=\"nowrap\">",
"     &lt;100/microL)",
"    </span>",
"    treated with intermittent antituberculous therapy (ie, once or twice weekly) rather than daily therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    is the cornerstone of all six-month regimens, resistance to this drug requires prolongation of treatment. Treatment regimens are based on large trials conducted prior to use of rifampin; success rates &gt;95 percent were documented with prolonged treatment. Acceptable regimens for rifampin monoresistant disease include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       Streptomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      given together for nine months. This regimen is the regimen of shortest duration for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      monoresistance, and good efficacy has been demonstrated in well-conducted clinical trials (in HIV-negative patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/31\">",
"       31",
"      </a>",
"      ]. However, it does entail nine months of injections. For treatment of HIV-infected patients whose sputum cultures do not convert during the first two months of treatment, some favor extending duration of treatment to 12 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/18,31\">",
"       18,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       Isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      given together for at least 12 months; some favor treatment for 18 months after culture conversion. In addition, some favor adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      for the first two to three months of treatment, or the addition of a quinolone, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      , throughout [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The addition of a fluoroquinolone to the regimen is reasonable although this has not been evaluated in clinical trials.",
"   </p>",
"   <p>",
"    It is reasonable to prolong therapy for an additional three months in HIV-infected patients.",
"   </p>",
"   <p>",
"    Of the 14 mutant RNA polymerase alleles, which confer resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , 9 also confer high-level resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/32\">",
"     32",
"    </a>",
"    ]. Approximately 25 percent of rifampin-resistant clinical isolates are sensitive to rifabutin, which appears to be as clinically effective as rifampin in short-course regimens for patients with drug-sensitive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. However, no data are available regarding the use of short-course regimens containing rifabutin in patients with rifabutin-sensitive but rifampin-resistant disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pyrazinamide monoresistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    monoresistance requires a nine month regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    . This combination has a success rate &gt;96 percent in large trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Monoresistance to other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single drug resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , or second-line agents is of relatively little clinical significance. Patients can be treated with the standard initial phase (two months of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    ) followed by four months of isoniazid and rifampin; success rates of 97 percent have been reported for this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT OF MULTIDRUG-RESISTANT TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;multidrug-resistant tuberculosis&rdquo; (MDR-TB) refers to an isolate of M. tuberculosis that is resistant to at least",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and possibly additional chemotherapeutic agents. Patients with MDR-TB consist of those with primary drug resistance (eg, patients who contract a drug-resistant strain of M. tuberculosis in the absence of previous antituberculous therapy), and those with secondary drug resistance (eg patients who contract a susceptible strain but develop resistance during or following antituberculous therapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antituberculous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been few controlled trials of the therapy of MDR-TB; in general, the approach is based upon clinical experience in patients who had been previously treated and relapsed, as well as prevailing practices at referral centers for MDR-TB cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/40\">",
"     40",
"    </a>",
"    ]. Even in somewhat resource-limited settings, good outcomes can be achieved with carefully chosen regimens and programs to increase adherence to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8895662\">",
"    <span class=\"h3\">",
"     Available agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available antituberculous agents are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef83653 \" href=\"mobipreview.htm?42/59/43964\">",
"     table 3",
"    </a>",
"    ). First-line agents for treatment of susceptible disease consist of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    . Second-line agents include late generation fluoroquinolones (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    ), injectable agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ), and other less effective agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    , and aminosalicylic acid). Other drugs for which clinical data are sparse include clofazimine, amoxicillin-clavulanic acid,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , carbapenems, thioacetazone, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8895717\">",
"    <span class=\"h4\">",
"     First-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line agents for treatment of susceptible TB consist of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef83653 \" href=\"mobipreview.htm?42/59/43964\">",
"     table 3",
"    </a>",
"    ). The clinical approach to use of these agents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8896537\">",
"    <span class=\"h4\">",
"     Second-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major categories of second-line agents for treatment of resistant TB disease include fluoroquinolones and injectable aminoglycosides (",
"    <a class=\"graphic graphic_table graphicRef83653 \" href=\"mobipreview.htm?42/59/43964\">",
"     table 3",
"    </a>",
"    ). Other less effective second-line agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    , and aminosalicylic acid. Alternative agents for which clinical data are sparse include clofazimine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , carbapenems, thioacetazone, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    . Dosing for second-line agents are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef66493 \" href=\"mobipreview.htm?13/8/13453\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8895813\">",
"    <span class=\"h5\">",
"     Fluoroquinolones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolones have excellent activity against M. tuberculosis and are used widely for treatment of MDR-TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Data on the relative clinical efficacy of fluoroquinolones are limited; in general, the later generation fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    ) are favored over the early generation fluoroquinolones (eg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and sparfloxacin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus far,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    appears to be the most effective fluoroquinolone for treatment of MDR-TB and is favored by the WHO MDR-TB treatment guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/45\">",
"     45",
"    </a>",
"    ];",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    are also good therapeutic options (although gatifloxacin has been associated with dysglycemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/46\">",
"     46",
"    </a>",
"    ]. Data supporting use of levofloxacin (1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    come from a small randomized trial and a pharmacokinetic study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Prior to these studies, data on levofloxacin administered at a lower dose (500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    suggested that levofloxacin was less effective than moxifloxacin or gatifloxacin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     Moxifloxacin",
"    </a>",
"    has bactericidal activity against M. tuberculosis; in vitro it is the most effective fluoroquinolone, followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Clinical studies have not included direct comparison between moxifloxacin and high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    , but have shown that moxifloxacin and gatifloxacin may be superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/53\">",
"     53",
"    </a>",
"    ]. There are good clinical data demonstrating that moxifloxacin may be a suitable alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    for patients infected with isoniazid-resistant M. tuberculosis; in a study of 328 participants with active pulmonary TB randomized to receive isoniazid or moxifloxacin (in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ), culture negativity after eight weeks was comparable between the groups (55 and 60 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/24\">",
"     24",
"    </a>",
"    ]. Data are conflicting regarding whether substituting moxifloxacin for ethambutol (in addition to treatment with isoniazid, rifampin, and pyrazinamide) hastens sputum culture conversion at eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    appears to be less clinically effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ; in a Cochrane meta-analysis evaluating ten randomized trials including 1178 participants with culture positive pulmonary TB treated with regimens containing fluoroquinolones, use of ciprofloxacin for treatment of drug-sensitive TB was associated with an increased incidence of relapse and longer time to sputum conversion compared with ofloxacin, levofloxacin, and moxifloxacin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no role for use of more than one fluoroquinolone in an MDR-TB treatment regimen since all drugs in the class share a genetic target, the gyrA gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/45,49,57,58\">",
"     45,49,57,58",
"    </a>",
"    ]. One retrospective study suggested that cross-resistance between fluoroquinolones is not always complete; it noted that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    was more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    for treatment of patients with ofloxacin-susceptible as well as ofloxacin-resistant strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fluoroquinolones are generally well tolerated; rare complications include tenosynovitis (including reports of Achilles' tendinitis and rupture) and cardiac conduction abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28618?source=see_link\">",
"     \"Fluoroquinolones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8898496\">",
"    <span class=\"h5\">",
"     Injectable agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of MDR-TB should always include an injectable drug; these bactericidal agents include the aminoglycosides (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    (a polypeptide). The choice of agent depends on a patient&rsquo;s previous injectable agent use (if any) and likelihood of resistance. Among injectable agents the order of preference for clinical use is: capreomycin, then kanamycin, then amikacin (streptomycin should not be used given widespread resistance).",
"   </p>",
"   <p>",
"    The injectable agent of choice is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    , although several factors limit its use (including limited availability, short shelf-life (24 months), limited access to electrolyte monitoring, and cost) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/62\">",
"     62",
"    </a>",
"    ]. In many countries,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    is the first-choice injectable agent, since it is relatively inexpensive and readily available. In general,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    should be avoided as a first-choice injectable agent given issues related to cross-resistance and risk of adverse events compared with other injectable drugs, even though it is the most widely available injectable agent given its broad activity against a range of organisms.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    should never be used to treat MDR-TB, even if drug susceptibility tests indicate a susceptible isolate, since the clinical reliability of this test is not very high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/63\">",
"     63",
"    </a>",
"    ]. Primary resistance to streptomycin is very common, especially in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    -resistant MDR-TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above approach is based in part upon laboratory data regarding resistance among the injectable agents, which may be summarized as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/62,65-67\">",
"     62,65-67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolates with acquired",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      resistance are usually susceptible to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"       kanamycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/59/11189?source=see_link\">",
"       capreomycin",
"      </a>",
"      . Rarely, single-step mutations conferring resistance to both streptomycin and kanamycin have been observed.",
"     </li>",
"     <li>",
"      Isolates with acquired",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/59/11189?source=see_link\">",
"       capreomycin",
"      </a>",
"      resistance are usually susceptible to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"       kanamycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      ; a few may be resistant to kanamycin and even fewer may be resistant to amikacin.",
"     </li>",
"     <li>",
"      Most isolates with acquired",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      resistance are resistant to both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"       kanamycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/59/11189?source=see_link\">",
"       capreomycin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Isolates with acquired",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"       kanamycin",
"      </a>",
"      resistance demonstrate variable levels of cross-resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/59/11189?source=see_link\">",
"       capreomycin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for acquired resistance during to injectable second line drugs include age 25 to 44 years, HIV infection, MDR-TB at time of treatment initiation, and treatment with any second line drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/68\">",
"     68",
"    </a>",
"    ]. In such patients, susceptibility monitoring for acquired resistance may be useful.",
"   </p>",
"   <p>",
"    There is no role for use of more than one injectable agent in an MDR-TB treatment regimen given a common mechanism of action (eg, protein synthesis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/45,57,58\">",
"     45,57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who cannot tolerate repeated intramuscular injections, intravenous therapy may be administered.",
"   </p>",
"   <p>",
"    The aminoglycosides can cause nephrotoxicity and eighth cranial nerve damage.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/59/11189?source=see_link\">",
"     Capreomycin",
"    </a>",
"    can cause electrolyte disorders, particularly hypokalemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/69\">",
"     69",
"    </a>",
"    ]. Renal function should be assessed regularly, and audiometry performed on a monthly basis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8896121\">",
"    <span class=\"h5\">",
"     Other second-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other second-line antituberculous drugs include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    , and aminosalicylic acid. These agents are substantially less effective for treatment of TB than the first-line agents, fluoroquinolones or injectable agents discussed in the preceding sections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/70\">",
"     70",
"    </a>",
"    ]. Ethionamide, cycloserine, and aminosalicylic acid belong to different drug classes, so more than one of these agents can be used to complete a regimen so that it consists of at least four active drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/45,57,58\">",
"     45,57,58",
"    </a>",
"    ]. Ideally the sequence for use should be ethionamide, then cycloserine, then aminosalicylic acid; this approach is based on efficacy, adverse events, and cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/15,62\">",
"     15,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/16/42244?source=see_link\">",
"     Ethionamide",
"    </a>",
"    inhibits mycolic acid synthesis and is structurally similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    with a shared molecular target [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/71\">",
"     71",
"    </a>",
"    ]; some cross-resistance between ethionamide and isoniazid has been observed. Ethionamide can cause gastrointestinal upset, hepatitis, neurologic reactions, and hypothyroidism.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"     Cycloserine",
"    </a>",
"    blocks enzymes required for mycobacterial cell wall formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/70\">",
"     70",
"    </a>",
"    ]. Cycloserine has been associated with a variety of adverse psychological effects, including psychosis, anxiety, and severe depression. Pyridoxine (vitamin B6) should be co-administered (at a dose of 50 mg for every 250 mg of cycloserine) to reduce the risk of neurotoxicity.",
"   </p>",
"   <p>",
"    Aminosalicylic acid inhibits the growth of M. tuberculosis by interfering with folate metabolism. Formulations include aminosalicylic acid and aminosalicylic sodium (which requires refrigeration). In general, this agent has limited efficacy, is poorly tolerated (due to gastrointestinal side effects), and is expensive. An enteric-coated formulation may have fewer gastrointestinal side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H403071\">",
"    <span class=\"h4\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative agents include drugs with relatively low efficacy or for which clinical data are sparse. For clinical circumstances in which it is necessary use agents in this group, at least two such drugs should be administered. The agents should be used in the following order of preference: clofazimine, amoxicillin-clavulanic acid,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , carbapenems, thioacetazone, then",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clofazimine is a part of standard TB treatment regimens in some regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/73\">",
"     73",
"    </a>",
"    ]; in general, its availability is limited to regions where it&rsquo;s used for the treatment of leprosy. The mechanism of action is still being elucidated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Adverse effects include photosensitivity, skin discoloration, and gastric intolerance.",
"   </p>",
"   <p>",
"    Amoxicillin-clavulanic acid combined with other second-line drugs has been used successfully to treat some patients with MDR-TB in anecdotal reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/76\">",
"     76",
"    </a>",
"    ]. M. tuberculosis is resistant to beta-lactam antibiotics in vitro but resistance can be overcome by inhibiting the beta-lactamase.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    has modest bactericidal activity against TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/77-80\">",
"     77-80",
"    </a>",
"    ] and efficacy has been observed among relatively small numbers of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/78,81-83\">",
"     78,81-83",
"    </a>",
"    ]. Its use is limited by adverse events (bone marrow suppression, neuropathy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/84\">",
"     84",
"    </a>",
"    ] and cost.",
"   </p>",
"   <p>",
"    Carbapenems (imipenem and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ) are active in vitro against M. tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/85\">",
"     85",
"    </a>",
"    ] and some clinical efficacy has been observed in a small number of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/86\">",
"     86",
"    </a>",
"    ]. Their use is limited by high cost, intravenous administration, and limited clinical experience.",
"   </p>",
"   <p>",
"    Thioacetazone has bacteriostatic activity against TB. Toxicity is high, particularly among patients with HIV infection. Its use should be restricted to cases with broad resistance with close follow-up, and should never be administered to patients with HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/87\">",
"     87",
"    </a>",
"    ]; use in this group is associated with high frequency of Stevens-Johnson syndrome.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    is not very effective against M. tuberculosis; data are limited to a small number of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Its use should be restricted to severe cases in which no other active drug is available, and in such cases its contribution will not be substantial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3115421\">",
"    <span class=\"h4\">",
"     New agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12869?source=see_link\">",
"     Bedaquiline",
"    </a>",
"    (Sirturo), the diarylquinoline TMC207, is a bactericidal antituberculous agent with a novel mechanism of mycobacterial ATP synthase inhibition. Among 440 patients with multidrug resistant TB (MDR-TB) in two phase 2 clinical trials, those who received bedaquiline in combination with optimized background regimens had faster and more frequent conversion to negative sputum culture than patients receiving the background regimens only (77.6 versus 57.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12869?source=see_link\">",
"     bedaquiline",
"    </a>",
"    received accelerated approval by the US Food and Drug Administration (FDA) in December 2012 for use as part of combination therapy to treat adults with multidrug resistant pulmonary TB when other alternatives are not available. A black box warning alerts that bedaquiline can cause QT prolongation, which could lead to cardiac arrhythmia. In data submitted to the FDA, death, most often from tuberculosis, was observed more frequently among patients receiving treatment with bedaquiline than among those treated with background regimens only (11.4 versus 2.5 percent). Therefore, the drug should be used only for patients who do not have other treatment options.",
"   </p>",
"   <p>",
"    Delamanid, a novel nitro-dihydro-imidazooxazole drug, inhibits mycolic acid synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/92\">",
"     92",
"    </a>",
"    ]. PA-824, a nitroimidazole, has bactericidal activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/93\">",
"     93",
"    </a>",
"    ]. Preliminary clinical trial results for these agents appear promising. The optimal approach to clinical use of these agents in combination regimens remains uncertain and requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Clinical approach",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3115902\">",
"    <span class=\"h4\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, treatment of suspected MDR-TB should be guided by drug susceptibility testing whenever possible. Oftentimes, susceptibility data is not available (at least initially), and empiric therapy must be used.",
"   </p>",
"   <p>",
"    Empiric regimens for patients in areas with a known high prevalence of MDR-TB (or for patients with a new diagnosis of TB following contact with an individual known to have MDR-TB) should include first-line agents plus whatever additional drugs are necessary to ensure that at least four drugs active against the most prevalent drug-resistant strains are included in the regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/17,94\">",
"     17,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drugs are chosen with a stepwise selection through the categories of antituberculous drugs (",
"    <a class=\"graphic graphic_table graphicRef83653 \" href=\"mobipreview.htm?42/59/43964\">",
"     table 3",
"    </a>",
"    ), on the basis of efficacy, safety, and cost. In general, treatment of MDR-TB should include a fluoroquinolone and an injectable agent (although there is no role for use of more than one fluoroquinolone or injectable agent). Subsequently, if needed,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    , and aminosalicylic acid may be added to complete the regimen such that it consists of at least four active drugs. Alternative agents should be added only when the preceding drugs are not sufficient.",
"   </p>",
"   <p>",
"    Repeat sputum smear microscopy with culture should be obtained two months after initiation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/15\">",
"     15",
"    </a>",
"    ]. If positive, evaluation should be repeated at the end of the third month of treatment; if positive, drug susceptibility testing should be performed. (See",
"    <a class=\"local\" href=\"#H3115947\">",
"     'Treatment failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The duration of the intensive phase of treatment (which includes administration of an injectable drug) should be at least six to eight months (or four months after culture conversion). The duration of the continuation phase of treatment (which consists of oral therapy in the absence of an injectable drug) should last until 18 to 24 months after culture conversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/15,17,62,94\">",
"     15,17,62,94",
"    </a>",
"    ]. In addition, consideration of surgery is warranted under specific circumstances. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment regimens should be tailored based on drug susceptibility data. If full drug susceptibility is documented, the additional drugs may be discontinued and standard regimens given until completion.",
"   </p>",
"   <p>",
"    If MDR-TB is documented, drugs to which the isolate is resistant should be discontinued, and new drugs should be added such that at least four drugs active against the most prevalent drug-resistant strains are included in the regimen based on the sequence outlined above. These regimens should be administered by direct observation.",
"   </p>",
"   <p>",
"    Management of these difficult cases should be handled by medical personnel with expertise and experience in administering complicated antituberculous regimens, and appropriate laboratory facilities to document drug susceptibility and monitor response should be available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Directly observed therapy (DOT) is mandatory for all patients with drug-resistant TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/95\">",
"     95",
"    </a>",
"    ]. Compliance with MDR-TB therapy is particularly difficult because regimens are prolonged and employ drugs with considerable adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10341?source=see_link\">",
"     \"Adherence to tuberculosis treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3115840\">",
"    <span class=\"h4\">",
"     Children and pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of children with MDR-TB is similar to adults, and can be treated successfully with rare adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/96\">",
"     96",
"    </a>",
"    ]. This is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23625?source=see_link&amp;anchor=H23631564#H23631564\">",
"     \"Tuberculosis disease in children\", section on 'Drug-resistant TB'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal approach to treatment of pregnant women with MDR-TB is uncertain. In general, studies performed in Peru have demonstrated that birth outcomes among pregnant women treated for MDR-TB are comparable to those among the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/97\">",
"     97",
"    </a>",
"    ], although the experience with treatment of MDR-TB in pregnancy is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/97\">",
"     97",
"    </a>",
"    ]. In a case series describing the long-term follow-up of six children with intrauterine exposure to second-line agents during treatment of MDR-TB during pregnancy, there was no evidence of significant toxicity among the children (average age at follow-up 3.7 years); one child was diagnosed with MDR-TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3115947\">",
"    <span class=\"h3\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure refers to failure of cultures to become negative during the course of treatment, or reappearance of positive cultures after the cultures convert to negative during treatment. Treatment failure implies resistance to all of the drugs being administered at the time when failure is diagnosed. The relatively poor response of drug resistant TB to treatment is likely a function of the relatively weak potency of the drugs used rather than the inherent properties of the microbe.",
"   </p>",
"   <p>",
"    Drug susceptibility testing is required in order to develop a new treatment regimen. Regimens for treatment of patients with MDR-TB should be established after careful review of previous medications and adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/17\">",
"     17",
"    </a>",
"    ]. Any agent taken for more than 30 days is likely to have decreased efficacy. Susceptibility testing must be performed, and therapy adjusted accordingly. An empiric retreatment regimen should include at least four drugs likely to be effective. This usually entails use of a regimen with greater toxicity than the prior regimen. Patients with treatment failure should receive highest priority for directly observed therapy (DOT).",
"   </p>",
"   <p>",
"    Therapeutic drug level monitoring may be useful in patients who do not respond to a seemingly appropriate regimen administered with DOT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/99\">",
"     99",
"    </a>",
"    ]. Low serum levels of anti-TB drugs have been reported in patients with malabsorption and in some individuals with HIV infection (even in the absence of clinical malabsorption) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with localized disease who are at high risk for relapse may benefit from surgical resection. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is most effective for patients with localized pulmonary disease which can be completely resected. Patients most likely to benefit from surgical intervention include those with sputum cultures positive for longer than three months despite appropriate therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with isolates resistant to all of the first-line oral agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/102-105\">",
"     102-105",
"    </a>",
"    ]. Frequently antituberculous therapy is administered for one to three months prior to surgery to reduce the mycobacterial burden. Resection alone should not be considered curative; patients with MDR-TB should continue antituberculous therapy for 18 months following surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes after treatment of MDR-TB have been evaluated in retrospective reviews from centers in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/1,106\">",
"     1,106",
"    </a>",
"    ] and in other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/88,107,108\">",
"     88,107,108",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients presenting with MDR-TB had been previously treated with a median of five to six drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/1,106\">",
"       1,106",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The overall success rate was similar in reports from resource-limited countries (Turkey, Latvia, others) and the United States (52 to 77 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/88,106-110\">",
"       88,106-110",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Predictors of successful therapy included surgical intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/106\">",
"       106",
"      </a>",
"      ], fluoroquinolone use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/88,106\">",
"       88,106",
"      </a>",
"      ], and younger age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/88\">",
"       88",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The outcome of patients with MDR-TB appears to vary with HIV status. In one retrospective review of 48 cases of MDR-TB, cure was observed in 97 percent of HIV-negative patients, with one relapse five years after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/107\">",
"     107",
"    </a>",
"    ]. In contrast, all 11 HIV-positive patients died; only two received antiretroviral therapy (ART); it is possible that early institution of ART could lead to better outcomes.",
"   </p>",
"   <p>",
"    Time to sputum culture conversion is a useful interim indicator of treatment outcome in patients with MDR-TB. In a study of 167 patients in Latvia with MDR-TB, conversion to negative cultures at a median time of 60 days occurred in 77 percent of patients; conversion was not observed in 23 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/111\">",
"     111",
"    </a>",
"    ]. Predictors of a longer conversion time included prior treatment for MDR-TB, high colony count on initial sputum culture, bilateral cavitation on chest radiography, and greater drug resistance at time of treatment initiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3116272\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best way to prevent multidrug-resistant tuberculosis (TB) is by prompt institution of appropriate therapy with efforts to guarantee adherence to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3116374\">",
"    <span class=\"h2\">",
"     Healthcare workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spread of infection can be reduced with proper infection control. However, there may be circumstances in which ongoing exposure to cases of multidrug-resistant TB (MDR-TB) on a regular basis is unavoidable (such as healthcare workers in facilities that treat significant numbers of MDR-TB patients). In these instances, consideration may be given to vaccination with Bacille Calmette-Gu&eacute;rin (BCG), although use of the BCG vaccine for the prevention of MDR-TB is not well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/113\">",
"     113",
"    </a>",
"    ]. BCG vaccine is 70 to 80 percent protective for prevention of TB in children, and is most useful for prevention of meningitis and disseminated disease. The efficacy of BCG among individuals first immunized as adults is expected to be lower than the efficacy in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/114\">",
"     114",
"    </a>",
"    ]. BCG should not be administered to patients with HIV infection or other forms of immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40136?source=see_link\">",
"     \"BCG vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful contact investigation is needed to evaluate drug-resistant TB exposure; the role of the health department is vital in this regard. After a thorough contact investigation, an estimate should be made both of the likelihood of recent infection with a resistant strain and the risk of the contact developing active TB. These factors should then be weighed against the risks of preventive regimens of unknown benefit before therapy is prescribed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Exposure to isoniazid monoresistant TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contacts of patients with INH monoresistant TB can be treated for two months with the combination of a rifamycin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/18,116\">",
"     18,116",
"    </a>",
"    ]. A four to six month regimen of a rifamycin alone is acceptable in patients who cannot tolerate pyrazinamide; we favor six months of therapy in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Exposure to rifampin monoresistant TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contacts of patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    monoresistant TB can be treated with the usual",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    regimen given to patients with exposure to drug-sensitive organisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Exposure to multidrug-resistant tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of contacts to MDR-TB cases is difficult because there are few published data concerning the composition, duration, or efficacy of preventive regimens for MDR-TB. Potential regimens that have been suggested (based primarily on animal studies) include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , or pyrazinamide and a quinolone, with drugs given in the doses to treat active disease for 12 months in immunocompromised patients, and at least six months in patients who are immunocompetent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/52/32586/abstract/116\">",
"     116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3118802\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term &ldquo;drug-resistant TB&rdquo; refers to cases of TB caused by an isolate of M. tuberculosis that is resistant to one of the first-line anti-TB drugs:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      . The term &ldquo;multidrug-resistant TB&rdquo; (MDR-TB) refers to an isolate of M. tuberculosis that is resistant to at least isoniazid and rifampin, and possibly additional agents. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to initiation of treatment, a careful history must be obtained for clues that drug resistance may be present. Sputum should be collected for baseline culture and sensitivity data prior to initiation of treatment. Rapid testing is an increasingly utilized tool for prompt detection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      resistance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       Isoniazid",
"      </a>",
"      monoresistant TB may be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      administered for six to nine months. Rifampin monoresistant TB may be treated with isoniazid, pyrazinamide, and an injectable agent administered for nine months. The addition of a fluoroquinolone to the regimen is reasonable although data are limited. It is reasonable to prolong therapy for an additional three months in HIV-infected patients. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of monoresistant TB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric regimens for patients suspected or known MDR-TB should include first-line agents plus additional drugs chosen via stepwise selection through the categories of antituberculous drugs (",
"      <a class=\"graphic graphic_table graphicRef83653 \" href=\"mobipreview.htm?42/59/43964\">",
"       table 3",
"      </a>",
"      ), such that at least four active drugs are included in the regimen (",
"      <a class=\"graphic graphic_table graphicRef66493 \" href=\"mobipreview.htm?13/8/13453\">",
"       table 2",
"      </a>",
"      ). In general, treatment should include a fluoroquinolone and an injectable agent. Subsequent agents that may be added if needed include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/16/42244?source=see_link\">",
"       ethionamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"       cycloserine",
"      </a>",
"      , and aminosalicylic acid. Alternative agents should be added only when the preceding drugs are not sufficient. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of the intensive phase of treatment (which includes administration of an injectable drug) should be at least six to eight months (or four months after culture conversion). The duration of the continuation phase of treatment (which consists of oral therapy in the absence of an injectable drug) should last until 18 to 24 months after culture conversion. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery is most effective for patients with localized pulmonary disease that can be completely resected. Patients most likely to benefit from surgical intervention include those with sputum cultures positive for longer than three months despite appropriate therapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those with isolates resistant to all of the first-line oral agents. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treating contacts of patients with INH monoresistant TB for two months with the combination of a rifamycin (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      ) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest treating contacts of patients with rifampin monoresistant TB with the usual",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      regimen given to patients with exposure to drug-sensitive organisms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment for contacts of patients with MDR-TB should be individualized based on the susceptibility profile of the index case; two drugs to which the organism is sensitive should be chosen, such as a combination of pyrazinamide plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      or a fluoroquinolone. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Contacts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/1\">",
"      Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization (WHO). Laboratory XDR-TB definitions. Geneva: Meeting of the global XDR TB task force 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/3\">",
"      Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 2009; 136:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/4\">",
"      Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/5\">",
"      Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/6\">",
"      Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009; 48:1354.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/tb/publications/global_report/2009/update/en/index.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/8\">",
"      Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/9\">",
"      Schluger NW, Rom WN. Current approaches to the diagnosis of active pulmonary tuberculosis. Am J Respir Crit Care Med 1994; 149:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/10\">",
"      Fitzwater SP, Caviedes L, Gilman RH, et al. Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy. Clin Infect Dis 2010; 51:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/11\">",
"      Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/12\">",
"      Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/13\">",
"      Jacobson KR, Theron D, Kendall EA, et al. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 2013; 56:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/14\">",
"      Choi JH, Lee KW, Kang HR, et al. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest 2010; 137:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/15\">",
"      Falzon D, Jaramillo E, Sch&uuml;nemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/16\">",
"      Minion J, Leung E, Menzies D, Pai M. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/17\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/18\">",
"      Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/19\">",
"      Cattamanchi A, Dantes RB, Metcalfe JZ, et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009; 48:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/20\">",
"      Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1987; 136:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/21\">",
"      Cynamon MH, Zhang Y, Harpster T, et al. High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection. Antimicrob Agents Chemother 1999; 43:2922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/22\">",
"      Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6:e1000150.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical policies and protocols. Chest Clinics, Bureau of Tuberculosis Control, New York City Department of Health.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/24\">",
"      Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/25\">",
"      Bang D, Andersen PH, Andersen AB, Thomsen V&Oslash;. Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. J Infect 2010; 60:452.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Treatment of tuberculosis: Guidelines --- 4th ed, Geneva 2010. whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf (Accessed on May 03, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/27\">",
"      Sandman L, Schluger NW, Davidow AL, Bonk S. Risk factors for rifampin-monoresistant tuberculosis: A case-control study. Am J Respir Crit Care Med 1999; 159:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/28\">",
"      Lutfey M, Della-Latta P, Kapur V, et al. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996; 153:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/29\">",
"      Nolan CM, Williams DL, Cave MD, et al. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med 1995; 152:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/30\">",
"      Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/31\">",
"      Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. Am Rev Respir Dis 1977; 115:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/32\">",
"      Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22 Suppl 1:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/33\">",
"      Schwander S, R&uuml;sch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis 1995; 76:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/34\">",
"      McGregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/35\">",
"      Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. Tuber Lung Dis 1994; 75:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/36\">",
"      Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1975; 1:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/37\">",
"      Stead WW, Dutt AK. Chemotherapy for tuberculosis today. Am Rev Respir Dis 1982; 125:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/38\">",
"      Dutt AK, Jones L, Stead WW. Short-course chemotherapy of tuberculosis with largely twice-weekly isoniazid-rifampin. Chest 1979; 75:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/39\">",
"      Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990; 112:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/40\">",
"      Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/41\">",
"      Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359:563.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis (monograph). World Health Organization, Geneva 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/43\">",
"      Peloquin CA. Quinolones and tuberculosis. Ann Pharmacother 1996; 30:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/44\">",
"      Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117:744.",
"     </a>",
"    </li>",
"    <li>",
"     WHO 2007. Guidelines for the programmatic management of drug-resistant tuberculosis. file://www.who.int/tb/features_archive/xdr_mdr_policy_guidance/en/index.html (Accessed on May 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/46\">",
"      Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/47\">",
"      Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/48\">",
"      Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/49\">",
"      Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/50\">",
"      Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/51\">",
"      Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/52\">",
"      Pletz MW, De Roux A, Roth A, et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/53\">",
"      Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 2008; 12:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/54\">",
"      Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/55\">",
"      Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/56\">",
"      Ziganshina LE, Vizel AA, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2005; :CD004795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/57\">",
"      Caminero JA, World Health Organization, American Thoracic Society, British Thoracic Society. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10:829.",
"     </a>",
"    </li>",
"    <li>",
"     WHO 2006. Guidelines for the programmatic management of drug-resistant tuberculosis. file://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf (Accessed on May 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/59\">",
"      Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/60\">",
"      Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/61\">",
"      Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21:253S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/62\">",
"      Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/63\">",
"      Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25:564.",
"     </a>",
"    </li>",
"    <li>",
"     The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance: Anti-tuberculosis drug resistance in the world, report No 4. World Health Organization 2008; 394: 1&ndash;120. file://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf (Accessed on May 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/65\">",
"      Alangaden GJ, Kreiswirth BN, Aouad A, et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/66\">",
"      Kr&uuml;&uuml;ner A, Jureen P, Levina K, et al. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:2971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/67\">",
"      Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49:3192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/68\">",
"      Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP. Acquired resistance to second-line drugs among persons with tuberculosis in the United States. Clin Infect Dis 2012; 55:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/69\">",
"      Shin S, Furin J, Alc&aacute;ntara F, et al. Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis. Chest 2004; 125:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/70\">",
"      David HL, Laszlo A, Rastogi N. Mode of action of antimycobacterial drugs. Acta Leprol 1989; 7 Suppl 1:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/71\">",
"      Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/72\">",
"      Peloquin CA, Henshaw TL, Huitt GA, et al. Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy 1994; 14:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/73\">",
"      Van Deun A, Salim MA, Das AP, et al. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/74\">",
"      Jagannath C, Reddy MV, Kailasam S, et al. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med 1995; 151:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/75\">",
"      Reddy VM, Nadadhur G, Daneluzzi D, et al. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob Agents Chemother 1996; 40:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/76\">",
"      Nadler JP, Berger J, Nord JA, et al. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991; 99:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/77\">",
"      Alcal&aacute; L, Ruiz-Serrano MJ, P&eacute;rez-Fern&aacute;ndez Tur&eacute;gano C, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003; 47:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/78\">",
"      Ntziora F, Falagas ME. Linezolid for the treatment of patients with [corrected] mycobacterial infections [corrected] a systematic review. Int J Tuberc Lung Dis 2007; 11:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/79\">",
"      Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008; 178:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/80\">",
"      Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/81\">",
"      Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/82\">",
"      Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/83\">",
"      Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/84\">",
"      Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/85\">",
"      Watt B, Edwards JR, Rayner A, et al. In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tuber Lung Dis 1992; 73:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/86\">",
"      Chambers HF, Turner J, Schecter GF, et al. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005; 49:2816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/87\">",
"      Elliott AM, Foster SD. Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection. Tuber Lung Dis 1996; 77:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/88\">",
"      Tahaolu K, T&ouml;r&uuml;n T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/89\">",
"      Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/90\">",
"      Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/91\">",
"      Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56:3271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/92\">",
"      Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/93\">",
"      Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/94\">",
"      Drugs for tuberculosis. Treat Guidel Med Lett 2004; 2:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/95\">",
"      Schluger N, Ciotoli C, Cohen D, et al. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med 1995; 151:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/96\">",
"      Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012; 186:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/97\">",
"      Palacios E, Dallman R, Mu&ntilde;oz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009; 48:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/98\">",
"      Drobac PC, del Castillo H, Sweetland A, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents. Clin Infect Dis 2005; 40:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/99\">",
"      Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clin Lab Med 1996; 16:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/100\">",
"      Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/101\">",
"      Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/102\">",
"      Sung SW, Kang CH, Kim YT, et al. Surgery increased the chance of cure in multi-drug resistant pulmonary tuberculosis. Eur J Cardiothorac Surg 1999; 16:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/103\">",
"      Souilamas R, Riquet M, Barthes FP, et al. Surgical treatment of active and sequelar forms of pulmonary tuberculosis. Ann Thorac Surg 2001; 71:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/104\">",
"      Pomerantz BJ, Cleveland JC Jr, Olson HK, Pomerantz M. Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg 2001; 121:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/105\">",
"      Somocurcio JG, Sotomayor A, Shin S, et al. Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax 2007; 62:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/106\">",
"      Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/107\">",
"      Burgos M, Gonzalez LC, Paz EA, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005; 40:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/108\">",
"      Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/109\">",
"      Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/110\">",
"      Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006; 12:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/111\">",
"      Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/112\">",
"      Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis--critical steps for prevention and control. N Engl J Med 2010; 363:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/113\">",
"      The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/114\">",
"      von Reyn CF, Vuola JM. New vaccines for the prevention of tuberculosis. Clin Infect Dis 2002; 35:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/115\">",
"      Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep 1992; 41:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/52/32586/abstract/116\">",
"      Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8028 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-189.41.172.26-5796C5686A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32586=[""].join("\n");
var outline_f31_52_32586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3118802\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Culture and sensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rapid testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15478205\">",
"      - Nucleic acid tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15478213\">",
"      - Culture based tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT OF MONORESISTANT TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Isoniazid monoresistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rifampin monoresistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pyrazinamide monoresistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Monoresistance to other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT OF MULTIDRUG-RESISTANT TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antituberculous therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8895662\">",
"      - Available agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8895717\">",
"      First-line agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8896537\">",
"      Second-line agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H8895813\">",
"      - Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H8898496\">",
"      - Injectable agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H8896121\">",
"      - Other second-line agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H403071\">",
"      Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3115421\">",
"      New agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3115902\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3115840\">",
"      Children and pregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3115947\">",
"      - Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3116272\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3116374\">",
"      Healthcare workers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Contacts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Exposure to isoniazid monoresistant TB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Exposure to rifampin monoresistant TB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Exposure to multidrug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3118802\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8028\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8028|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/12/25804\" title=\"table 1\">",
"      First-line TB drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/8/13453\" title=\"table 2\">",
"      Second line TB drugs for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/59/43964\" title=\"table 3\">",
"      Categories of antituberculous drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10341?source=related_link\">",
"      Adherence to tuberculosis treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40136?source=related_link\">",
"      BCG vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7497?source=related_link\">",
"      Epidemiology and molecular mechanisms of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34743?source=related_link\">",
"      Epidemiology of extensively drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_52_32587="Percutaneous transtracheal ventilation complications";
var content_f31_52_32587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential complications of needle cricothyroidotomy and percutaneous transtracheal ventilation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Category",
"      </td>",
"      <td class=\"subtitle1\">",
"       Complication",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Unsuccessful catheter placement",
"       <strong>",
"        OR",
"       </strong>",
"       Successful catheter placement with subsequent obstruction, kinking, or dislodgement",
"      </td>",
"      <td>",
"       Inability to ventilate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Subcutaneous emphysema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Barotrauma",
"      </td>",
"      <td>",
"       Subcutaneous emphysema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pneumomediastinum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pneumothorax",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pneumatocele of the larynx",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Damage to adjacent structures",
"      </td>",
"      <td>",
"       Posterior tracheal laceration or perforation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Esophageal perforation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mediastinitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vocal cord injury",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Laryngeal injury and/or laryngospasm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Excessive bleeding",
"      </td>",
"      <td>",
"       Hematoma (cutaneous and/or airway) with extrinsic or intrinsic airway narrowing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Infection",
"      </td>",
"      <td>",
"       Cellulitis and abscess (cutaneous and/or prevertebral)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tracheitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Osteomyelitis of the cervical spine",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32587=[""].join("\n");
var outline_f31_52_32587=null;
var title_f31_52_32588="Education at 1st follow up";
var content_f31_52_32588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delivery of asthma education by clinicians during patient care visits: recommendations for first followup visit (two to four weeks or sooner as needed)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Assessment questions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Focus on:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Concerns",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Quality of life",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Expectations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Goals of treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Ask relevant questions from previous visit and also ask:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"            \"What medications are you taking?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"How and when are you taking them?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What problems have you had using your medications?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"Please show me how you use your inhaled medications?\"",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Information",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review in simple language:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use two types of medications. Remind patient to bring all medications and the peak flow meter to every appointment for review.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Self-evaluation of progress in asthma control using symptoms and peak flow as a guide.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review and demonstrate:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use of a daily self-management plan. Review and adjust as needed.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use of an action plan. Review and adjust as needed.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Peak flow monitoring and daily diary recording.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Correct inhaler and spacer/holding chamber technique.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32588=[""].join("\n");
var outline_f31_52_32588=null;
var title_f31_52_32589="Preventing doxorubicin toxicity - Impact of following guidelines";
var content_f31_52_32589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Cardiotoxicity of doxorubicin with and without monitoring guidelines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 282px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier plot describes the probability of survival without clinical heart failure (HF) in patients whose management was either concordant or discordant with the guideline criteria for monitoring patients receiving doxorubicin. Patients managed by the guidelines had a fourfold reduction in the incidence of clinical HF independent of other predictor variables.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Schwartz RG, McKenzie WB, Alexander J, et al, Am J Med 1987; 82:1109.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32589=[""].join("\n");
var outline_f31_52_32589=null;
var title_f31_52_32590="Occiput posterior position";
var content_f31_52_32590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Occiput posterior position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32590=[""].join("\n");
var outline_f31_52_32590=null;
var title_f31_52_32591="Standard needle knife approach";
var content_f31_52_32591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Needle-knife approach for precut sphincterotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A common method of performing needle-knife sphincterotomy is to use the elevator to direct the needle-knife while incising the papilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas A Howell, MD and David J Desilets, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_52_32591=[""].join("\n");
var outline_f31_52_32591=null;
